WO2024211130A1

WO2024211130A1 - Methods for modifying meiotic recombination in plants

Info

Publication number: WO2024211130A1
Application number: PCT/US2024/021556
Authority: WO
Inventors: Jonathan T. VOGEL; Matthias Witschel; Charles W. Finch; Greg COPENHAVER
Original assignee: University of North Carolina at Chapel Hill; BASF Corp
Current assignee: University of North Carolina at Chapel Hill; BASF Corp
Priority date: 2023-04-05
Filing date: 2024-03-27
Publication date: 2024-10-10
Anticipated expiration: 2025-10-05

Abstract

Described herein are compounds for modifying meiotic recombination in a plant. In addition, described herein are methods of modifying meiotic recombination in a plant, including methods that can reduce linkage drag in a plant, increase recombination in a cold region of the genome of a plant, and/or reduce the number of backcross generations in a plant breeding method.

Description

COMPOUNDS FOR MODIFYING MEIOTIC RECOMBINATION AND METHODS RELATING THERETO FIELD [0001] This invention relates to compounds for modifying meiotic recombination in a plant and to methods relating thereto such as methods of modifying meiotic recombination in a plant. BACKGROUND OF THE INVENTION [0002] Meiosis is the specialized form of cell division, common to all sexually reproducing organisms, that reduces the genomic compliment by half in preparation for fertilization, and produces gametes (sperm or eggs). During meiosis, most organisms shuffle genetic information between the homologous chromosomes they inherited from their parents in a process called recombination. Meiotic recombination produces novel combinations of the versions of the genes (alleles) carried on each parental chromosome which in turn causes genetic and phenotypic variation. Generating and selecting desirable variation is the basis for all commercial plant breeding. [0003] During breeding programs there are times when it is beneficial to have high levels of recombination so that desirable traits can be separated from undesirable ones – this is often referred to as avoiding “linkage drag”. At other times it is beneficial to have low levels of recombination so that multiple linked desirable traits can be maintained as a group. Breeders typically approach these problems in two ways. They can screen large populations that are “segregating” the traits of interest to identify the individuals that express the desired trait(s) but lack the undesirable trait(s). Segregating populations are created by crossing parents that have different genotypes at one or more loci in their genome (genetic polymorphisms). The resulting F1 (first filial) progeny are heterozygous at the polymorphic loci. F1 progeny are then crossed with one another or allowed to self-fertilize to generate F2 (second filial generation) progeny; or backcrossed to one of the parents to generate BC1 (fist backcross generation) progeny; or outcrossed to another line to create outcrossed progeny. The meiotic recombination that occurs during the production of gametes by the F1 individuals generates new combinations of alleles in the subsequent progeny generations. Because the new combinations of alleles differ between F2, or BC1 or outcrossed individuals those generations are said to be "segregating" the alleles. Breeders apply their selection schemes to these segregating populations, but this is expensive, laborious, time consuming and difficult to scale. Alternatively, they can use genetic engineering to influence the genes than regulate meiotic recombination, but this approach has consumer acceptance issues. Accordingly, new methods that can modify meiotic recombination would be advantageous. SUMMARY OF THE INVENTION [0004] A first aspect of the present invention is directed to a method of modifying meiotic recombination in a plant, the method comprising: applying a compound that modulates meiotic recombination to the plant, thereby modifying meiotic recombination in the plant. [0005] A further aspect of the present invention is directed to a method of reducing linkage drag in a plant, increasing recombination in a cold region of a plant genome, and/or reducing the number of backcross generations in a plant breeding method, the method comprising: applying a compound that modulates meiotic recombination to a plant, thereby reducing linkage drag in the plant, increasing recombination in a cold region of the genome of the plant, and/or reducing the number of backcross generations in a plant breeding method including the plant. [0006] It is noted that aspects of the invention described with respect to one embodiment, may be incorporated in a different embodiment although not specifically described relative thereto. That is, all embodiments and/or features of any embodiment can be combined in any way and/or combination. Applicant reserves the right to change any originally filed claim and/or file any new claim accordingly, including the right to be able to amend any originally filed claim to depend from and/or incorporate any feature of any other claim or claims although not originally claimed in that manner. These and other objects and/or aspects of the present invention are explained in detail in the specification set forth below. Further features, advantages and details of the present invention will be appreciated by those of ordinary skill in the art from a reading of the figures and the detailed description of the preferred embodiments that follow, such description being merely illustrative of the present invention. DETAILED DESCRIPTION [0007] The present invention now will be described hereinafter with reference to the accompanying drawings and examples, in which embodiments of the invention are shown. This description is not intended to be a detailed catalog of all the different ways in which the invention [0008] may be implemented, or all the features that may be added to the instant invention. For example, features illustrated with respect to one embodiment may be incorporated into other embodiments, and features illustrated with respect to a particular embodiment may be deleted from that embodiment. Thus, the invention contemplates that in some embodiments of the invention, any feature or combination of features set forth herein can be excluded or omitted. In addition, numerous variations and additions to the various embodiments suggested herein will be apparent to those skilled in the art in light of the instant disclosure, which do not depart from the instant invention. Hence, the following descriptions are intended to illustrate some particular embodiments of the invention, and not to exhaustively specify all permutations, combinations and variations thereof. [0009] Unless otherwise defined, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this invention belongs. The terminology used in the description of the invention herein is for the purpose of describing particular embodiments only and is not intended to be limiting of the invention. [0010] All publications, patent applications, patents and other references cited herein are incorporated by reference in their entireties for the teachings relevant to the sentence and/or paragraph in which the reference is presented. [0011] Unless the context indicates otherwise, it is specifically intended that the various features of the invention described herein can be used in any combination. Moreover, the present invention also contemplates that in some embodiments of the invention, any feature or combination of features set forth herein can be excluded or omitted. To illustrate, if the specification states that a composition comprises components A, B and C, it is specifically intended that any of A, B or C, or a combination thereof, can be omitted and disclaimed singularly or in any combination. [0012] As used in the description of the invention and the appended claims, the singular forms "a," "an" and "the" are intended to include the plural forms as well, unless the context clearly indicates otherwise. [0013] Also as used herein, "and/or" refers to and encompasses any and all possible combinations of one or more of the associated listed items, as well as the lack of combinations when interpreted in the alternative ("or"). [0014] The term "about," as used herein when referring to a measurable value such as an amount or concentration and the like, is meant to encompass variations of ± 10%, ± 5%, ± 1%, ± 0.5%, or even ± 0.1% of the specified value as well as the specified value. For example, "about X" where X is the measurable value, is meant to include X as well as variations of ± 10%, ± 5%, ± 1%, ± 0.5%, or even ± 0.1% of X. A range provided herein for a measurable value may include any other range and/or individual value therein. [0015] As used herein, phrases such as "between X and Y" and "between about X and Y" should be interpreted to include X and Y. As used herein, phrases such as "between about X and Y" mean "between about X and about Y" and phrases such as "from about X to Y" mean "from about X to about Y." [0016] Recitation of ranges of values herein are merely intended to serve as a shorthand method of referring individually to each separate value falling within the range, unless otherwise indicated herein, and each separate value is incorporated into the specification as if it were individually recited herein. For example, if the range 10 to 15 is disclosed, then 11, 12, 13, and 14 are also disclosed. [0017] The term "comprise," "comprises" and "comprising" as used herein, specify the presence of the stated features, integers, steps, operations, elements, and/or components, but do not preclude the presence or addition of one or more other features, integers, steps, operations, elements, components, and/or groups thereof. [0018] As used herein, the transitional phrase "consisting essentially of" means that the scope of a claim is to be interpreted to encompass the specified materials or steps recited in the claim and those that do not materially affect the basic and novel characteristic(s) of the claimed invention. Thus, the term "consisting essentially of" when used in a claim of this invention is not intended to be interpreted to be equivalent to "comprising." [0019] As used herein, the terms "increase," "increasing," "enhance," "enhancing," "improve" and "improving" (and grammatical variations thereof) describe an elevation of at least about 5%, 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 100%, 150%, 200%, 300%, 400%, 500% or more such as compared to another measurable property or quantity (e.g., a control value). [0020] As used herein, the terms "reduce," "reduced," "reducing," "reduction," "diminish," and "decrease" (and grammatical variations thereof), describe, for example, a decrease of at least about 5%, 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 97%, 98%, 99%, or 100% such as compared to another measurable property or quantity (e.g., a control value). In some embodiments, the reduction can result in no or essentially no (i.e., an insignificant amount, e.g., less than about 10% or even 5%) detectable activity or amount. [0021] According to embodiments of the present invention provided are compounds that can modulate (e.g., increase or decrease) meiotic recombination in a plant. In addition, provided according to embodiments of the present invention is a method of modifying meiotic recombination in a plant, the method comprising applying to the plant a compound that modulates meiotic recombination, thereby modifying meiotic recombination in the plant. In some embodiments, a method of the present invention comprises reducing linkage drag in a plant, increasing recombination in a cold region of the genome a plant, and/or reducing the number of backcross generations in a plant breeding method including a plant, the method comprising applying a compound that modulates meiotic recombination to the plant to thereby reduce linkage drag in the plant, increase recombination in a cold region of the genome of the plant, and/or reduce or eliminate the number of backcross generations in a plant breeding method including the plant. [0022] In some embodiments, a method of the present invention is devoid of genetic engineering to modify meiotic recombination in the plant. A method of the present invention may not rely on and/or involve stable transgenic changes to a plant’s genome. In some embodiments, a method of the present invention may accelerate genetic gain in a plant breeding method and/or decrease breeding time, optionally in a non-genetically modified fashion. [0023] A method of the present invention and/or a compound that modulates meiotic recombination of the present invention may increase the frequency of meiotic recombination events that occur in the genome of a plant. Meiotic recombination is initiated by double strand breaks (DSBs) in the DNA (e.g., DSBs in chromosomes) of plants. During meiotic recombination DSBs are repaired. DSB repair can be mediated by multiple molecular pathways including: "double strand break repair' (DSBR), "synthesis dependent strand annealing" (SDSA), MUS81-dependent repair, YEN1/GEN1-dependent repair, double- holiday junction dissolution, non-homologous end joining (NHEJ), break-induced repair (BIR), one-sided DSB repair, gap repair, and sister-chromatid exchange (SCE). These pathways can result in crossovers (CO; reciprocal exchange of DNA between homologous chromosomes), non-crossover (NCO; repair without reciprocal exchange of DNA between homologous chromosomes), or non-homologous rearrangements (for example translocations or inversions). All of these recombination products can also be accompanied by "gene conversion" (GC) which is the conversion of sequence information from allele to another. Among these products of meiotic recombination, the frequency of meiotic crossover events is a limiting factor in breeding programs. Thus, increasing the frequency of meiotic recombination in a plant, which can include increasing the number of crossovers that occur during meiosis in a cell of the plant, may reduce linkage drag, increase recombination in a cold region of the genome of the plant, and/or reduce or eliminate the number of backcross generations in a plant breeding method including the plant. In some embodiments, a method of the present invention decreases the frequency of meiotic recombination in a plant (e.g., decreases the number of crossovers that occur during meiosis in a cell of the plant), which may allow for two or more (e.g., 2, 3, 4, or more) desirable traits that are optionally linked to be maintained as a group. An increase or decrease in the frequency of meiotic recombination in a plant can be compared to the frequency of meiotic recombination in a control plant and/or a parent plant. A “control plant” as used herein refers to a plant of the same species, breeding line, variety, and/or cultivar as the plant to which a compound that modulates meiotic recombination is applied, but a compound that modulates meiotic recombination of the present invention is not applied to the control plant. In some embodiments, the method comprises comparing a plant of the present invention and a control plant that are grown under the same growth conditions, e.g., the same environmental conditions (e.g., soil, hydration, light, heat, and/or nutrient conditions, and/or the like). In some embodiments, an increase or decrease in the frequency of meiotic recombination is determined by comparing the frequency of meiotic recombination in the gametes of a parent plant and in the gametes of a progeny plant that is the progeny of the parent plant and wherein a compound that modulates meiotic recombination is applied to the progeny plant, optionally wherein the parent plant and progeny plant are grown under the same growth conditions. [0024] A method of the present invention may comprise determining an increase or decrease in the frequency of meiotic recombination in a plant. In some embodiments, determining an increase or decrease in the frequency of meiotic recombination in a plant may comprise measuring the frequency of meiotic recombination using a visual fluorescent pollen transgene assay (e.g., a pollen tetrad-based visual assay). In some embodiments, determining an increase or decrease in the frequency of meiotic recombination in a plant may comprise measuring the frequency of meiotic recombination using the polymerase chain reaction (PCR) method to measure the segregation of one or more linked molecular markers (DNA polymorphisms). In some embodiments, determining an increase or decrease in the frequency of meiotic recombination in a plant may comprise measuring the frequency of meiotic recombination using nucleic acid sequencing (e.g., high through^put sequencing and/or next generation sequencing (NGS)). In some embodiments, determining an increase or decrease in the frequency of meiotic recombination in a plant may comprise measuring the frequency of meiotic recombination by scoring the segregation loci that express observable phenotypes encoded by one or more linked loci. The GLABROUS1 gene in Arabidopsis thaliana is an example of a locus that can be used as an observable marker. Functional alleles of GLABROUS1 allow trichomes to develop on the leaves and organs while non-functional alleles result in a smooth phenotype. Several such phenotypic markers have been described in the literature. Loci that express observable phenotypes can be native to the host genome or transgenes. In some embodiments, a method of the present invention comprises genotyping, optionally wherein the genotyping comprises sequencing a polynucleotide and/or the genome of a gamete and/or pollen of the plant to which a compound that modulates meiotic recombination is applied; sequencing a polynucleotide and/or the genome of a gamete and/or pollen of the plant to which a compound that modulates meiotic recombination is not applied (e.g., a control and/or parent plant), and comparing the sequences to thereby quantify the frequency of meiotic recombination (e.g., the number of crossovers). [0025] A visual fluorescent pollen transgene assay may be performed as described in Francis et al., Proc Natl Acad Sci USA.2007; 104(10):3913-3918, Modliszewski et al., PLoS Genet, 2018, 14(5): e1007384, and/or Berchowitz, L. and Copenhaver, G. Nature Protocols, 2008; 3(1), 41-50, the contents of each of which are incorporated herein by reference in their entirety. In some embodiments, measuring the frequency of meiotic recombination using a visual fluorescent pollen transgene assay comprises providing a plant that comprises a nucleotide sequence encoding one or more (e.g., 1, 2, 3, 4, 5, or more) pollen- expressed fluorescent protein(s) that are different from each other (e.g., each protein fluoresces a different color) and/or a nucleotide sequence encoding one or more (e.g., 1, 2, 3, 4, 5, or more) gamete-expressed fluorescent protein(s) that are different from each other. A visual fluorescent pollen transgene assay can employ linked transgenes encoding differently colored fluorescent proteins that are expressed under the control of a post-meiotic, pollen- and/or gamete specific protomer (e.g., a LAT52 promoter) and, by observing the segregation pattern of the fluorescent proteins in pollen tetrads (e.g., by using fluorescence microscopy), the number of crossovers can be quantified. In some embodiments, the method may comprise observing about 1, 10, 50, 100, 150, or 200 to about 250, 300, 350, 400, 450, 500, or more pollen tetrads to determine the segregation pattern of the fluorescent proteins in pollen tetrads and quantify the number of crossovers. [0026] In some embodiments, a method of the present invention may comprise generating a plant that comprises a fluorescent protein (optionally two or more different fluorescent proteins), optionally by transforming the plant with a nucleotide sequence that encodes the fluorescent protein to provide a plant encoding the fluorescent protein, wherein the location of the nucleotide sequence encoding the fluorescent protein in the genome of the plant allows for the frequency of meiotic recombination to be quantified (e.g., in one or more gamete- and/or pollen-expressed fluorescent protein(s)); selecting seed from the plant comprising the fluorescent protein, wherein the seed comprises the nucleotide sequence encoding the fluorescent protein in its genome; growing the seed into a parent plant; measuring the frequency of meiotic recombination in the parent plant by examining and/or determining the fluorescent signal and/or fluorescent pattern from pollen tetrads produced by the parent plant; generating a progeny plant from the plant, optionally by selfing the parent plant; applying a compound that modulates meiotic recombination to the progeny plant; measuring the frequency of meiotic recombination in the progeny plant by examining and/or determining the fluorescent signal and/or fluorescent pattern from pollen tetrads produced by the progeny plant; and determining whether there is an increase or decrease in the frequency of meiotic recombination by comparing the frequency of meiotic recombination in the parent plant and progeny plant. [0027] In some embodiments, a method of the present invention may comprise generating a plant that comprises a fluorescent protein (optionally two or more different fluorescent proteins), optionally by transforming the plant with a nucleotide sequence that encodes the fluorescent protein provide a plant encoding the fluorescent protein, wherein the location of the nucleotide sequence encoding the fluorescent protein in the genome of the plant allows for the frequency of meiotic recombination to be quantified (e.g., in one or more gamete- and/or pollen-expressed fluorescent protein(s)); selecting a plurality of seeds from the plant comprising the nucleotide sequence encoding the fluorescent protein, wherein each seed of the plurality of seeds comprises the nucleotide sequence encoding the fluorescent protein in its genome; growing the plurality of seeds into a plurality of plants, wherein the plurality of plants comprises a first population of plants and a second population of plants; applying a compound that modulates meiotic recombination to the first population of plants, wherein the compound that modulates meiotic recombination is not applied to the second population of plants; measuring the frequency of meiotic recombination in one or more plants in first population of plants and in one or more plants in the second population of plants by examining and/or determining the fluorescent signal and/or fluorescent pattern from pollen tetrads produced by the respective plant; and determining whether there is an increase or decrease in the frequency of meiotic recombination by comparing the frequency of meiotic recombination in the one or more plants in the first population of plants and the frequency of meiotic recombination in the one or more plants in the second population of plants. [0028] A method of the present invention may modify and/or affect one or more pathways involved in meiotic recombination. In some embodiments, a method of the present invention modifies a pathway involved in double-strand break formation, double-strand break end resection, strand invasion, D-loop formation, D-loop extension, second-end capture, formation of recombination intermediates including holliday junctions and double-holliday junctions, DNA synthesis in meiotic recombination, holliday junction resolution, helicase activity, crossover formation, formation of non-reciprocal exchanges, DNA methylation, post-translational histone modification, distribution of histone variants, heat stress, cold stress, pathogen stress, and/or a pathway as described in Wang, Y. and Copenhaver, G., Annu. Rev. Plant Biol.2018.69:577–609, the contents of which are incorporated herein by reference in its entirety. In some embodiments, a method of the present invention may increase expression and/or activity of a nucleic acid and/or protein in a plant and/or may decrease expression and/or activity of a nucleic acid and/or protein in a plant. The nucleic acid and/or protein may be involved in a meiotic recombination pathway. Exemplary nucleic acids and/or proteins encoded thereby whose expression and/or production may be increased or decreased by a method of the present invention include, but are not limited to, SPO11-1, SPO11-2, MTOPVIB, PRD1, PRD2, PRD3, DFO, PCH2, PHS1, MRE11, RAD50, NBS1, RAD51, DMC1, POL2A, RFC1, POLD1, MUS81, MSH4, MSH5, HEI10, MLH, FANCM, FIGL1, Ku70/80, Ku70/80, MRE11, PARP1, RAD51, ATM, H2AX, COM1/SAE2, Ku70/80, and/or PARP1, and/or a protein encoded thereby. Further exemplary proteins whose expression and/or production may be increased or decreased by a method of the present invention include, but are not limited to, a histone deacetylase inhibitor, a DNA methyltransferase (e.g., CMT3), a H3K4me3 demethylase inhibitor (e.g., LSD1), a histone deacetylase inhibitor, an inhibitor of H3K9 methylation (e.g., SDG21 and/or SUVH4/5/6), heat shock protein 90 (HSP90), Bloom syndrome protein (BLM), RECQL4, TOP3A, and/or DNA ligase IV. In some embodiments, a method of the present invention may increase or decrease expression, production, and/or activity of an enzyme in a plant. [0029] Applying the compound that modulates meiotic recombination to the plant comprises contacting (e.g., exogenously contacting) the compound to at least a portion of the plant. In some embodiments, applying the compound that modulates meiotic recombination to the plant comprises spraying (e.g., foliar spraying), drenching, injecting, dipping, soaking, and/or the like the compound that modulates meiotic recombination onto at least a portion of the plant. In some embodiments, the compound that modulates meiotic recombination is present in a composition (e.g., an aqueous composition) and the composition is contacted to the plant (e.g., sprayed, dipped, soaked, injected, drenched, and/or the like onto the plant). In some embodiments, the compound that modulates meiotic recombination is contacted to the plant by contacting soil adjacent to the plant with the compound that modulates meiotic recombination and/or by soil drenching (e.g., drenching the soil around the plant with the compound that modulates meiotic recombination). In some embodiments, a compound that modulates meiotic recombination can be present in a hydroponic solution and/or applied to a plant as a liquid, solid, paste, gel, and/or gas. A compound that modulates meiotic recombination can be taken up by vegetative tissue of a plant such as leaves and/or stems; reproductive tissue of a plant such as flowers, anthers, pollen mother cells, ovaries, ovules, and/or megaspore mother cells; a root; and/or by entry through a stomatal opening. [0030] In some embodiments, a compound that modulates meiotic recombination may act on a cell that is undergoing meiosis or is developmentally fated to undergo meiosis (e.g., a meiocyte). A compound that modulates meiotic recombination may be applied to a plant such that the compound acts on a vegetative cell which then differentiates into a meiocyte. In some embodiments, a compound that modulates meiotic recombination may act on a vegetive cell which produces a signal that is received by the meiocyte and/or acts on a cell that will differentiate into a meiocyte. Signals can be communicated cell-to-cell or across tissues, including from the root to the shoot and/or to a floral tissue. In some embodiments, a compound that modulates meiotic recombination that is applied to a plant may produce a persistent or transient effect. A compound that modulates meiotic recombination may be applied to a plant and may act within a single generation, or it can be applied in one generation and influence two or more (e.g., 2, 3, 4, 5, or more) subsequent generations. Plants have an alternation of generation life cycle, so generations include both gametophyte and sporophyte phases. In some embodiments, a method of the present invention comprises applying a compound that modulates meiotic recombination to a plant at a time prior to, during, and/or after the transition from the vegetative phase to the reproductive phase of the plant. In some embodiments, a method of the present invention comprises applying a compound that modulates meiotic recombination to a plant during the plant’s reproductive phase. In some embodiments, a method of the present invention comprises applying a compound that modulates meiotic recombination to a cell of a plant, wherein the cell is a meiocyte and/or is undergoing meiosis, optionally wherein the cell is a vegetative cell. In some embodiments, a method of the present invention comprises applying a compound that modulates meiotic recombination to the sporophyte generation of a plant to modulate meiotic recombination in the gametophyte generation, and the gametophyte generation may have an increased number of crossovers compared to the gametophyte generation generated in the absence of a method of the present invention and/or the parent generation generated in the absence of a method of the present invention. [0031] A method of the present invention may comprise applying a compound that modulates meiotic recombination to a reproductive part of the plant (e.g., a flower bud, inflorescence, flower, stamen, pistil, etc.). In some embodiments, a method of the present invention comprises applying a compound that modulates meiotic recombination to an aerial part of the plant. In some embodiments, a method of the present invention comprises applying a compound that modulates meiotic recombination to a root of the plant. [0032] According to embodiments of the present invention, a compound that modulates meiotic recombination may be a compound that mimics temperature (e.g., heat and/or cold) shock in a plant, a compound that mimics pathogen stress in a plant, an allelopathic compound, a compound that inhibits non- homologous end joining (NHEJ) in a plant, a compound that affects helicase activity and/or formation in a plant, a compound that affects an epigenetic mark and/or epigenetic modifier in a plant, and/or a compound that affects a component used in a meiotic recombination pathway in a plant. In some embodiments, the compound that modulates meiotic recombination is selected from the group consisting of: ethyl 4-[(1- hydroxy-2-phenylindol-3-yl)-pyridin-2-ylmethyl]piperazine-1-carboxylate, N-(5-tert-butyl-1H-pyrazol-3- yl)-2-[(3R)-3-propan-2-ylpiperazin-1-yl]-7H-pyrrolo[2,3-d]pyrimidin-4-amine, N-(6-aminohexyl)-5- chloro-1-naphthalenesulfonamide, 2-chloro-10-(3-dimethylaminopropyl)phenothiazine hydrochloride, Z- 5-(4-hydroxybenzylidene)-2-imino-1,3-thiazolidin-4-one, 2-[(2R)-2-methylpyrrolidin-2-yl]-1H- benzimidazole-4-carboxamide, 5-[(E)-2-(4-hydroxyphenyl)ethenyl]benzene-1,3-diol, 3- (benzylsulfamoyl)-4-bromo-N-(4-bromophenyl)benzamide, 2-(4-Morpholinyl)-6-(1- thianthrenyl)-4H-Pyran-4-one, an azane, a dichloroplatinum(2+) compound, cisplatin, 2-(pyridin-3- ylmethylidene)indene-1,3-dione, [(1S,2S,4R)-4-[4-[[(1S)-2,3-dihydro-1H-inden-1- yl]amino]pyrrolo[2,3-d]pyrimidin-7-yl]-2-hydroxycyclopentyl]methyl sulfamate, 2-[2-(3,4- dimethoxyphenyl)ethylamino]-6-(3-fluorophenyl)-8H-pyrimido[4,5-d]pyrimidine-5,7-dione, 1-(4- ((dimethylamino)methyl)phenyl)-8,9-dihydro-2,7,9a-triazabenzo[cd]azulen-6(7H)-one, (2E,4E,6R)-7-[4- (dimethylamino)phenyl]-N-hydroxy-4,6-dimethyl-7-oxohepta-2,4-dienamide, 4-[(E)-2-(3,5- dimethoxyphenyl)ethenyl]phenol, 4-amino-N-(4,6-dimethylpyrimidin-2- yl)benzenesulfonamide, (2S)-2-amino-4-ethylsulfanylbutanoic acid, 4-amino-1-[(2R,3R,4S,5R)-3,4- dihydroxy-5-(hydroxymethyl)oxolan-2-yl]-1,3,5-triazin-2-one, sodium butanoate, 5,7-dihydroxy-3-(4- hydroxyphenyl)chromen-4-one, pyridine-2,4-dicarboxylic acid, (1R,2S)-2-phenylcyclopropan-1-amine, 4- amino-1-[(2R,4S,5R)-4-hydroxy-5-(hydroxymethyl)oxolan-2-yl]-1,3,5-triazin-2-one, 1-[(2R,3R,4S,5R)- 3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]pyrimidin-2-one, 3-[4-[(1R,2S)-2- aminocyclopropyl]phenyl]phenol, methyl 3-[4-(4- carbamimidoylbenzoyl)piperazine-1-carbonyl]-5-[(4-carbamimidoylpiperazin-1-yl)methyl]benzoate, 2- [[[2-[2-(dimethylamino)ethyl-ethylamino]-2-oxoethyl]amino]methyl]pyridine-4-carboxamide, 2-(4- methylphenyl)-1,2-benzothiazol-3-one, 5-chloro-N-[(E)-[phenyl(pyridin-2-yl)methylidene]amino]pyridin- 2-amine, methyl 2-benzamido-1-(3-phenylpropyl)benzimidazole-5-carboxylate, 2-[(2-hydroxynaphthalen- 1-yl)methylideneamino]-N-(1-phenylethyl)benzamide, 3-(prop-2-enyldisulfanyl)prop-1-ene, N-(1- benzylpiperidin-4-yl)-6,7-dimethoxy-2-(4-methyl-1,4-diazepan-1-yl)quinazolin-4-amine, 5'- methoxy-6'-(3-pyrrolidin-1-ylpropoxy)spiro[cyclobutane-1,3'-indole]-2'-amine, 2-cyclohexyl-6-methoxy- N-(1-propan-2-ylpiperidin-4-yl)-7-(3-pyrrolidin-1-ylpropoxy)quinazolin-4-amine, 7-[3- (dimethylamino)propoxy]-6-methoxy-2-(4-methyl-1,4-diazepan-1-yl)-N-(1-methylpiperidin-4- yl)quinazolin-4-amine, 14-(hydroxymethyl)-3-[14-(hydroxymethyl)-18-methyl-13,17-dioxo- 15,16-dithia-10,12,18-triazapentacyclo[12.2.2.01,12.03,11.04,9]octadeca-4,6,8-trien-3-yl]-18-methyl- 15,16-dithia-10,12,18-triazapentacyclo[12.2.2.01,12.03,11.04,9]octadeca-4,6,8-triene-13,17-dione, 2,3- dichloro-1,4-naphthoquinone, 2,3-dichloro-5,8-dihydroxy-1,4-naphthoquinone, (1S,2R,4S)-1,7,7- trimethylbicyclo[2.2.1]heptan-2-ol, 2-isothiocyanatoethylbenzene, 4-isothiocyanatobutylbenzene, 3- isothiocyanatoprop-1-ene, isothiocyanatoethane, 1-isothiocyanatobutane, 3-isothiocyanato-2-methylprop- 1-ene, [(4E,6Z,8S,9S,10E,12S,13R,14S,16R)-13-hydroxy-8,14,19-trimethoxy-4,10,12,16-tetramethyl- 3,20,22-trioxo-2-azabicyclo[16.3.1]docosa-1(21),4,6,10,18-pentaen-9-yl] carbamate, 4- [[(2R,3S,4R,5R)-5-[6-amino-8-[(3,4-dichlorophenyl)methylamino]purin-9-yl]-3,4-dihydroxyoxolan-2- yl]methoxymethyl]benzonitrile, 24-methyl-5,7,18,20-tetraoxa-24- azoniahexacyclo[11.11.0.02,10.04,8.014,22.017,21]tetracosa-1(24),2,4(8),9,11,13,15,17(21),22-nonaene, (4S)-4-prop-1-en-2-ylcyclohexene-1-carbaldehyde, (4R)-1-methyl-4-prop-1-en-2-ylcyclohexene,(1R,4R)- 1,7,7-trimethylbicyclo[2.2.1]heptan-2-one, 3,3-trimethyl-2-oxabicyclo[2.2.2]octane, 2,6,6- trimethylbicyclo[3.1.1]hept-2-ene, isothiocyanatobenzene, 2-isothiocyanatopropane, 1-isothiocyanato-2- methylpropane, 1-isothiocyanatohexane, 1-isothiocyanato-4-methylsulfinylbutane, 1-isothiocyanato-5- methylsulfinylpentane, 8-[(6-iodo-1,3-benzodioxol-5-yl)sulfanyl]-9-[3-(propan-2-ylamino)propyl]purin-6- amine, [4-[2-carbamoyl-5-[6,6-dimethyl-4-oxo-3-(trifluoromethyl)-5,7-dihydroindazol-1- yl]anilino]cyclohexyl] 2-aminoacetate, 3-(2,4-dihydroxy-5-propan-2-ylphenyl)-4-(1-methylindol-5-yl)- 1H-1,2,4-triazol-5-one, N-acetyl-5-methoxytryptamine, S-methyl 1,2,3-benzothiadiazole-7-carbothioate, 5-chloro-2-methylpyrazole-3-carboxylic acid, 3-prop-2-enoxy-1,2-benzothiazole 1,1-dioxide, 3- aminobutanoic acid, 1,1-dioxo-1,2-benzothiazol-3-one, 4-hydroxybenzohydrazide, 3-hydroxy-3-(2- oxopropyl)-1H-indol-2-one, 2-[3-[(4-amino-2-methylpyrimidin-5-yl)methyl]-4-methyl-1,3-thiazol-3-ium- 5-yl]ethanol, 2,6-dichloropyridine-4-carboxylic acid, 3-methoxybenzo[d]isothiazole 1,1-dioxide, N-(3- chloro-4-methylphenyl)-4-methylthiadiazole-5-carboxamide, 3,4-dichloro-N-(2-cyanophenyl)-1,2- thiazole-5-carboxamide, 2-amino-3,5-dichlorobenzoic acid, 3-(furan-2-yl)-3-phenylpropan-1-amine, 4- amino-N-(5-methoxypyrimidin-2-yl)benzenesulfonamide, 4-amino-N-(6-methoxypyridazin-3- yl)benzenesulfonamide, N-(4-aminophenyl)sulfonylbenzamide, 4-amino-N-(6-chloropyridazin-3- yl)benzenesulfonamide, 4-amino-N-(5-methyl-1,2-oxazol-3-yl)benzenesulfonamide, 3-(butylamino)-4- phenoxy-5-sulfamoylbenzoic acid, 3-benzyl-1,1-dioxo-6-(trifluoromethyl)-3,4-dihydro-2H-1^6,2,4- benzothiadiazine-7-sulfonamide, 4-chloro-N-[(2R,6S)-2,6-dimethylpiperidin-1-yl]- 3sulfamoylbenzamide,(3R,4S,5R,6R)-4-[(3R,4S,5R,6R)-3,5-dihydroxy-6-(hydroxymethyl)-4- [(3R,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyoxan-2-yl]oxy-6- (hydroxymethyl)oxane-2,3,5-triol, (3R,6S)-3-hydroxy-3-[(3-hydroxyphenyl)methyl]-1,4-dimethyl-6-[(4- nitro-1H-indol-3-yl)methyl]piperazine-2,5-dione, 2,4-dichloro-6-[(3-methoxyphenyl)iminomethyl]phenol, 1,2-benzothiazole 1,1-dioxide, 5-[(3-carboxy-4-hydroxyphenyl)-(3-carboxy-4-oxocyclohexa-2,5-dien-1- ylidene)methyl]-2-hydroxybenzoic acid, disodium 6-methyl-2-[4-[2-[4-(6-methyl-7-sulfonato-1,3- benzothiazol-2-yl)phenyl]iminohydrazinyl]phenyl]-1,3-benzothiazole-7-sulfonate, 8-[[4-methyl-3-[[3-[[3- [[2-methyl-5-[(4,6,8-trisulfonaphthalen-1- yl)carbamoyl]phenyl]carbamoyl]phenyl]carbamoylamino]benzoyl]amino]benzoyl]amino]naphth alene- 1,3,5-trisulfonic acid, 1-[4-Fluoro-3-(trifluoromethyl)phenyl]-3-(5-pyridin-4-yl-1,3,4-thiadiazol-2- yl)urea,3-[18-(2-carboxyethyl)-7,12-diethyl-3,8,13,17,22-pentamethyl-23H-porphyrin-2-yl]propanoic acid, 1h-pyrrole-2,5-dione, 1-[(1-oxopropoxy)methyl]-N-propionyloxymethyl-maleimide, 3,4-dichloro-1- [3-(3,4-dichloro-2,5-dioxopyrrol-1-yl)-2,2-dimethylpropyl]pyrrole-2,5-dione, 5,7-dioxa-12- azoniapentacyclo[10.6.1.02,10.04,8.015,19]nonadeca-1(18),2,4(8),9,11,15(19),16-heptaen-17-ol, 5,6- bis(((E)-benzylidene)amino)-2-thioxo-2,3-dihydropyrimidin-4(1H)-one, (6Z)-3,7,11-trimethyldodeca- 1,6,10-trien-3-ol, (2S,5R)-5-methyl-2-propan-2-ylcyclohexan-1-one, (1S,2S,5S,8R,9S,10S,11R,15S,18R)- 9,10,15,18-tetrahydroxy-12,12-dimethyl-6-methylidene-17- oxapentacyclo[7.6.2.15,8.01,11.02,8]octadecan-7-one, (1R,2R,5R,9R,12R,16R)-5-ethenyl- 1,5,12-trimethyl-10-oxatetracyclo[7.6.1.02,7.012,16]hexadec-7-ene-11,13-dione, (1S,2R,5R,12R,18R)-5- ethenyl-13-hydroxy-5,12-dimethyl-10,14-dioxapentacyclo[11.2.2.11,9.02,7.012,18]octadec-7-en-11-one, [(1R,2R,4S,6S,9R,10S,13S,16R)-2,16-dihydroxy-5,5,9-trimethyl-14-methylidene-15-oxo-6- tetracyclo[11.2.1.01,10.04,9]hexadecanyl] acetate, (1S,4S,8R,9R,12S,13S,14S,16S)-9,14- dihydroxy-7,7-dimethyl-17-methylidene-3,10-dioxapentacyclo[14.2.1.01,13.04,12.08,12]nonadecane- 2,18-dione, [(1S,1'R,3'S,5R,6S,7S,9S)-3'-acetyloxy-7-hydroxy-6',6'-dimethyl-10-methylidene-2,11- dioxospiro[3-oxatricyclo[7.2.1.01,6]dodecane-5,2'-cyclohexane]-1'-yl]methyl acetate, (3E,6E)-3,7,11- trimethyldodeca-1,3,6,10-tetraene, 6,6-dimethyl-2-methylidenebicyclo[3.1.1]heptane, 2,2-dimethyl-3- methylidenebicyclo[2.2.1]heptane, 5-methyl-2-propan-2-ylphenol, (2E)-3,7-dimethylocta-2,6-dien-1- ol,(2E)-3,7-dimethylocta-2,6-dienal, 5-methyl-2-propan-2-ylcyclohexan-1-ol, benzoic acid, 2- aminophenoxazin-3-one, 2-amino-7-methoxyphenoxazin-3-one, (2S,3R)-2-(3,4-dihydroxyphenyl)-3,4- dihydro-2H-chromene-3,5,7-triol, and any combination thereof. [0033] In some embodiments, a compound that modulates meiotic recombination is a compound that affects a component of and/or used in a meiotic recombination pathway in a plant. In some embodiments, a compound that modulates meiotic recombination is selected from the group consisting of: ethyl 4-[(1- hydroxy-2-phenylindol-3-yl)-pyridin-2-ylmethyl]piperazine-1-carboxylate, N-(5-tert-butyl-1H-pyrazol-3- yl)-2-[(3R)-3-propan-2-ylpiperazin-1-yl]-7H-pyrrolo[2,3-d]pyrimidin-4-amine, N-(6-aminohexyl)-5- chloro-1-naphthalenesulfonamide, 2-chloro-10-(3-dimethylaminopropyl)phenothiazine hydrochloride, Z-5- (4-hydroxybenzylidene)-2-imino-1,3-thiazolidin-4-one, 2-[(2R)-2-methylpyrrolidin-2-yl]-1H- benzimidazole-4-carboxamide, 5-[(E)-2-(4-hydroxyphenyl)ethenyl]benzene-1,3-diol, 3- (benzylsulfamoyl)-4-bromo-N-(4-bromophenyl)benzamide, 2-(4-Morpholinyl)-6-(1-thianthrenyl)-4H- Pyran-4-one, an azane, a dichloroplatinum(2+) compound, cisplatin, 2-(pyridin-3-ylmethylidene)indene- 1,3-dione, [(1S,2S,4R)-4-[4-[[(1S)-2,3-dihydro-1H-inden-1-yl]amino]pyrrolo[2,3-d]pyrimidin-7-yl]-2- hydroxycyclopentyl]methyl sulfamate, 2-[2-(3,4-dimethoxyphenyl)ethylamino]-6-(3- fluorophenyl)-8H-pyrimido[4,5-d]pyrimidine-5,7-dione, 1-(4-((dimethylamino)methyl)phenyl)-8,9- dihydro-2,7,9a-triazabenzo[cd]azulen-6(7H)-one, (2E,4E,6R)-7-[4-(dimethylamino)phenyl]-N-hydroxy- 4,6-dimethyl-7-oxohepta-2,4-dienamide, 4-[(E)-2-(3,5-dimethoxyphenyl)ethenyl]phenol, and any combination thereof. [0034] In some embodiments, a compound that modulates meiotic recombination is a compound that affects an epigenetic mark (e.g., DNA methylation, post-translational modification of histone tails, deposition of variant histones and/or the action of small RNAs) and/or an epigenetic modifier in a plant. In some embodiments, a compound that modulates meiotic recombination is selected from the group consisting of: 4-amino-N-(4,6-dimethylpyrimidin-2-yl)benzenesulfonamide, (2S)-2-amino-4- ethylsulfanylbutanoic acid, 4-amino-1-[(2R,3R,4S,5R)-3,4-dihydroxy-5- (hydroxymethyl)oxolan-2-yl]-1,3,5-triazin-2-one, sodium butanoate, 5,7-dihydroxy-3-(4- hydroxyphenyl)chromen-4-one, pyridine-2,4-dicarboxylic acid, (1R,2S)-2-phenylcyclopropan-1-amine, 4- amino-1-[(2R,4S,5R)-4-hydroxy-5-(hydroxymethyl)oxolan-2-yl]-1,3,5-triazin-2-one, 1-[(2R,3R,4S,5R)- 3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]pyrimidin-2-one, 3-[4-[(1R,2S)-2- aminocyclopropyl]phenyl]phenol, methyl 3-[4-(4-carbamimidoylbenzoyl)piperazine-1-carbonyl]-5-[(4- carbamimidoylpiperazin-1-yl)methyl]benzoate, 2-[[[2-[2-(dimethylamino)ethyl-ethylamino]-2- oxoethyl]amino]methyl]pyridine-4-carboxamide, 2-(4-methylphenyl)-1,2-benzothiazol-3-one, 5-chloro-N- [(E)-[phenyl(pyridin-2-yl)methylidene]amino]pyridin-2-amine, methyl 2-benzamido-1-(3- phenylpropyl)benzimidazole-5-carboxylate, 2-[(2-hydroxynaphthalen-1-yl)methylideneamino]-N-(1- phenylethyl)benzamide, 3-(prop-2-enyldisulfanyl)prop-1-ene, N-(1-benzylpiperidin-4-yl)-6,7-dimethoxy- 2-(4-methyl-1,4-diazepan-1-yl)quinazolin-4-amine, 5'-methoxy-6'-(3-pyrrolidin-1- ylpropoxy)spiro[cyclobutane-1,3'-indole]-2'-amine, 2-cyclohexyl-6-methoxy-N-(1-propan-2-ylpiperidin- 4-yl)-7-(3-pyrrolidin-1-ylpropoxy)quinazolin-4-amine, 7-[3-(dimethylamino)propoxy]-6-methoxy-2-(4- methyl-1,4-diazepan-1-yl)-N-(1-methylpiperidin-4-yl)quinazolin-4-amine, 14-(hydroxymethyl)-3-[14- (hydroxymethyl)-18-methyl-13,17-dioxo-15,16-dithia-10,12,18- triazapentacyclo[12.2.2.01,12.03,11.04,9]octadeca-4,6,8-trien-3-yl]-18-methyl-15,16-dithia-10,12,18- triazapentacyclo[12.2.2.01,12.03,11.04,9]octadeca-4,6,8-triene-13,17-dione, and any combination thereof. [0035] In some embodiments, a compound that modulates meiotic recombination may be a compound that mimics temperature shock in a plant. In some embodiments, the compound mimics heat shock (e.g., heat stress) in the plant and/or the compound mimics cold shock (e.g., cold stress) in the plant. In some embodiments, a compound that modulates meiotic recombination is selected from the group consisting of: 2,3-dichloro-1,4-naphthoquinone, 2,3-dichloro-5,8-dihydroxy-1,4-naphthoquinone, (1S,2R,4S)-1,7,7- trimethylbicyclo[2.2.1]heptan-2-ol, 2-isothiocyanatoethylbenzene, 4-isothiocyanatobutylbenzene, 3- isothiocyanatoprop-1-ene, isothiocyanatoethane, 1-isothiocyanatobutane, 3-isothiocyanato-2-methylprop- 1-ene, [(4E,6Z,8S,9S,10E,12S,13R,14S,16R)-13-hydroxy-8,14,19-trimethoxy-4,10,12,16-tetramethyl- 3,20,22-trioxo-2-azabicyclo[16.3.1]docosa-1(21),4,6,10,18-pentaen-9-yl] carbamate, 4- [[(2R,3S,4R,5R)-5-[6-amino-8-[(3,4-dichlorophenyl)methylamino]purin-9-yl]-3,4-dihydroxyoxolan-2- yl]methoxymethyl]benzonitrile, 24-methyl-5,7,18,20-tetraoxa-24- azoniahexacyclo[11.11.0.02,10.04,8.014,22.017,21]tetracosa-1(24),2,4(8),9,11,13,15,17(21),22-nonaene, (4S)-4-prop-1-en-2-ylcyclohexene-1-carbaldehyde, (4R)-1-methyl-4-prop-1-en-2-ylcyclohexene,(1R,4R)- 1,7,7-trimethylbicyclo[2.2.1]heptan-2-one, 1,3,3-trimethyl-2-oxabicyclo[2.2.2]octane, 2,6,6- trimethylbicyclo[3.1.1]hept-2-ene, isothiocyanatobenzene, 2-isothiocyanatopropane, 1-isothiocyanato-2- methylpropane, 1-isothiocyanatohexane, 1-isothiocyanato-4-methylsulfinylbutane, 1-isothiocyanato-5- methylsulfinylpentane, 8-[(6-iodo-1,3-benzodioxol-5-yl)sulfanyl]-9-[3-(propan-2-ylamino)propyl]purin-6- amine, [4-[2-carbamoyl-5-[6,6-dimethyl-4-oxo-3-(trifluoromethyl)-5,7-dihydroindazol-1- yl]anilino]cyclohexyl] 2-aminoacetate, 3-(2,4-dihydroxy-5-propan-2-ylphenyl)-4-(1-methylindol-5-yl)-1H- 1,2,4-triazol-5-one, and any combination thereof. In some embodiments, a compound that modulates meiotic recombination is N-acetyl-5-methoxytryptamine. [0036] In some embodiments, a compound that modulates meiotic recombination may be a compound that mimics pathogen stress in a plant. In some embodiments, a compound that modulates meiotic recombination is selected from the group consisting of: S-methyl 1,2,3-benzothiadiazole-7-carbothioate, 5-chloro-2-methylpyrazole-3-carboxylic acid, 3-prop-2-enoxy-1,2-benzothiazole 1,1-dioxide, 3- aminobutanoic acid, 1,1-dioxo-1,2-benzothiazol-3-one, 4-hydroxybenzohydrazide, 3-hydroxy-3-(2- oxopropyl)-1H-indol-2-one, 2-[3-[(4-amino-2-methylpyrimidin-5-yl)methyl]-4-methyl-1,3-thiazol-3-ium- 5-yl]ethanol, 2,6-dichloropyridine-4-carboxylic acid, 3-methoxybenzo[d]isothiazole 1,1-dioxide, N-(3- chloro-4-methylphenyl)-4-methylthiadiazole-5-carboxamide, 3,4-dichloro-N-(2-cyanophenyl)-1,2- thiazole-5-carboxamide, 2-amino-3,5-dichlorobenzoic acid, 3-(furan-2-yl)-3-phenylpropan-1-amine, 4- amino-N-(5-methoxypyrimidin-2-yl)benzenesulfonamide,4-amino-N-(6-methoxypyridazin-3- yl)benzenesulfonamide, N-(4-aminophenyl)sulfonylbenzamide, 4-amino-N-(6-chloropyridazin-3- yl)benzenesulfonamide, 4-amino-N-(5-methyl-1,2-oxazol-3-yl)benzenesulfonamide, 3- (butylamino)-4-phenoxy-5-sulfamoylbenzoic acid, 3-benzyl-1,1-dioxo-6-(trifluoromethyl)-3,4-dihydro- 2H-1^6,2,4-benzothiadiazine-7-sulfonamide, 4-chloro-N-[(2R,6S)-2,6-dimethylpiperidin-1-yl]-3- sulfamoylbenzamide, (3R,4S,5R,6R)-4-[(3R,4S,5R,6R)-3,5-dihydroxy-6-(hydroxymethyl)-4- [(3R,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyoxan-2-yl]oxy-6- (hydroxymethyl)oxane-2,3,5-triol, (3R,6S)-3-hydroxy-3-[(3-hydroxyphenyl)methyl]-1,4-dimethyl-6-[(4- nitro-1H-indol-3-yl)methyl]piperazine-2,5-dione, 2,4-dichloro-6-[(3-methoxyphenyl)iminomethyl]phenol, 1,2-benzothiazole 1,1-dioxide, and any combination thereof. [0037] In some embodiments, a compound that modulates meiotic recombination may be a compound that affects helicase activity and/or formation in a plant, optionally wherein the compound modulates the activity of an enzyme (e.g., a helicase). In some embodiments, a compound that modulates meiotic recombination is selected from the group consisting of: 5-[(3-carboxy-4-hydroxyphenyl)-(3-carboxy-4- oxocyclohexa-2,5-dien-1-ylidene)methyl]-2-hydroxybenzoic acid, disodium 6-methyl-2-[4-[2-[4-(6- methyl-7-sulfonato-1,3-benzothiazol-2-yl)phenyl]iminohydrazinyl]phenyl]-1,3-benzothiazole-7- sulfonate,8-[[4-methyl-3-[[3-[[3-[[2-methyl-5-[(4,6,8-trisulfonaphthalen-1- yl)carbamoyl]phenyl]carbamoyl]phenyl]carbamoylamino]benzoyl]amino]benzoyl]amino]naphth alene- 1,3,5-trisulfonic acid, 1-[4-Fluoro-3-(trifluoromethyl)phenyl]-3-(5-pyridin-4-yl-1,3,4-thiadiazol-2- yl)urea,3-[18-(2-carboxyethyl)-7,12-diethyl-3,8,13,17,22-pentamethyl-23H-porphyrin-2-yl]propanoic acid, 1h-pyrrole-2,5-dione, 1-[(1-oxopropoxy)methyl]-N-propionyloxymethyl-maleimide, 3,4-dichloro-1- [3-(3,4-dichloro-2,5-dioxopyrrol-1-yl)-2,2-dimethylpropyl]pyrrole-2,5-dione, and any combination thereof. [0038] In some embodiments, a compound that modulates meiotic recombination may be a compound that inhibits non-homologous end joining (NHEJ) in a plant. Meiotic recombination is initiated by the creation of double strand breaks (DSBs) in DNA. Several cellular pathways are capable of repairing DSBs, but homologous recombination (HR) is the primary pathway that is useful to breeders. In some embodiments, a method and/or compound that modulates meiotic recombination may inhibit a pathway that competes with HR, which may force the cell to rely more heavily on HR and may result in an increase in the frequency of meiotic recombination events. In some embodiments, a compound that modulates meiotic recombination is selected from the group consisting of: 5,7-dioxa-12- azoniapentacyclo[10.6.1.02,10.04,8.015,19]nonadeca-1(18),2,4(8),9,11,15(19),16-heptaen-17-ol, and any combination thereof. In some embodiments, a compound that modulates meiotic recombination is 5,6- bis(((E)-benzylidene)amino)-2-thioxo-2,3-dihydropyrimidin-4(1H)-one. [0039] In some embodiments, a compound that modulates meiotic recombination may be an allelopathic compound. In some embodiments, a compound that modulates meiotic recombination is selected from the group consisting of: (6Z)-3,7,11-trimethyldodeca-1,6,10-trien-3-ol, (2S,5R)-5-methyl-2- propan-2-ylcyclohexan-1-one, (1S,2S,5S,8R,9S,10S,11R,15S,18R)-9,10,15,18-tetrahydroxy-12,12- dimethyl-6-methylidene-17-oxapentacyclo[7.6.2.15,8.01,11.02,8]octadecan-7-one, (1R,2R,5R,9R,12R,16R)-5-ethenyl-1,5,12-trimethyl-10-oxatetracyclo[7.6.1.02,7.012,16]hexadec-7-ene- 11,13-dione, (1S,2R,5R,12R,18R)-5-ethenyl-13-hydroxy-5,12-dimethyl-10,14- dioxapentacyclo[11.2.2.11,9.02,7.012,18]octadec-7-en-11-one, [(1R,2R,4S,6S,9R,10S,13S,16R)-2,16- dihydroxy-5,5,9-trimethyl-14-methylidene-15-oxo-6-tetracyclo[11.2.1.01,10.04,9]hexadecanyl] acetate, (1S,4S,8R,9R,12S,13S,14S,16S)-9,14-dihydroxy-7,7-dimethyl-17-methylidene-3,10- dioxapentacyclo[14.2.1.01,13.04,12.08,12]nonadecane-2,18-dione, [(1S,1'R,3'S,5R,6S,7S,9S)-3'- acetyloxy-7-hydroxy-6',6'-dimethyl-10-methylidene-2,11-dioxospiro[3-oxatricyclo[7.2.1.01,6]dodecane- 5,2'-cyclohexane]-1'-yl]methyl acetate, (3E,6E)-3,7,11-trimethyldodeca-1,3,6,10-tetraene, 6,6- dimethyl-2-methylidenebicyclo[3.1.1]heptane, 2,2-dimethyl-3-methylidenebicyclo[2.2.1]heptane,5- methyl-2-propan-2-ylphenol, (2E)-3,7-dimethylocta-2,6-dien-1-ol, (2E)-3,7-dimethylocta-2,6-dienal,5- methyl-2-propan-2- ylcyclohexan-1-ol, benzoic acid, 2-aminophenoxazin-3-one, 2-amino-7- methoxyphenoxazin-3-one, (2S,3R)-2-(3,4-dihydroxyphenyl)-3,4-dihydro-2H-chromene-3,5,7-triol, and any combination thereof. [0040] In some embodiments, a method of the present invention comprises applying a compound that modulates meiotic recombination to a plant, wherein the compound is a compound of Table 1. In some embodiments, the method comprises applying two or more (e.g., 2, 3, 4, 5, or more) compounds of Table 1 to the plant. In some embodiments, the target and/or function of the compound modulates meiotic recombination is as provided in Table 1. Table 1: Exemplary target and/or exemplary function for a compound that modulates meiotic recombination of the present invention. Exemplary target and/or exemplary f^unction Compound that modulates meiotic recombination ethyl 4-[(1-hydroxy-2-phenylindol-3-yl)-pyridin-2-ylmethyl]piperazine- FANCM 1-carboxylate N-(5-tert-butyl-1H-pyrazol-3-yl)-2-[(3R)-3-propan-2-ylpiperazin-1-yl]-7H- FIGL1 pyrrolo[2,3-d]pyrimidin-4-amine Ku70/80 N-(6-aminohexyl)-5-chloro-1-naphthalenesulfonamide Ku70/80 2-chloro-10-(3-dimethylaminopropyl)phenothiazine hydrochloride MRE11 Z-5-(4-hydroxybenzylidene)-2-imino-1,3-thiazolidin-4-one PARP1 2-[(2R)-2-methylpyrrolidin-2-yl]-1H-benzimidazole-4-carboxamide RAD51 5-[(E)-2-(4-hydroxyphenyl)ethenyl]benzene-1,3-diol RAD51 3-(benzylsulfamoyl)-4-bromo-N-(4-bromophenyl)benzamide 2-(4-Morpholinyl)-6-(1-thianthrenyl)-4H-Pyran-4-one, 2-(Morpholin-4-yl)- ATM 6-(thianthren-1-yl)-4H-pyran-4-one [general] azane;dichloroplatinum(2+) H2AX 2-(pyridin-3-ylmethylidene)indene-1,3-dione COM1/SAE [(1S,2S,4R)-4-[4-[[(1S)-2,3-dihydro-1H-inden-1-yl]amino]pyrrolo[2,3- 2 d]pyrimidin-7-yl]-2-hydroxycyclopentyl]methyl sulfamate 2-[2-(3,4-dimethoxyphenyl)ethylamino]-6-(3-fluorophenyl)-8H- Ku70/80 pyrimido[4,5-d]pyrimidine-5,7-dione 1-(4-((dimethylamino)methyl)phenyl)-8,9-dihydro-2,7,9a- PARP1 triazabenzo[cd]azulen-6(7H)-one (2E,4E,6R)-7-[4-(dimethylamino)phenyl]-N-hydroxy-4,6-dimethyl-7- RAD51 oxohepta-2,4-dienamide RAD51 4-[(E)-2-(3,5-dimethoxyphenyl)ethenyl]phenol DNA methylation 4-amino-N-(4,6-dimethylpyrimidin-2-yl)benzenesulfonamide DNA methylation 2S)-2-amino-4-ethylsulfanylbutanoic acid DNA 4-amino-1-[(2R,3R,4S,5R)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2- methylation yl]-1,3,5-triazin-2-one Histone deacetylase inhibitor Sodium butanoate Non-CG DNA methylation, CMT3 5,7-dihydroxy-3-(4-hydroxyphenyl)chromen-4-one H3K4me3 demethylase inhibitor, LSD1 pyridine-2,4-dicarboxylic acid H3K4me3 demethylase inhibitor, LSD1 (1R,2S)-2-phenylcyclopropan-1-amine DNA 4-amino-1-[(2R,4S,5R)-4-hydroxy-5-(hydroxymethyl)oxolan-2-yl]- methylation 1,3,5-triazin-2-one DNA 1-[(2R,3R,4S,5R)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]pyrimidin- methylation 2-one H3K4me3 demethylase inhibitor, LSD1 3-[4-[(1R,2S)-2-aminocyclopropyl]phenyl]phenol H3K4me3 demethylase inhibitor, methyl 3-[4-(4-carbamimidoylbenzoyl)piperazine-1-carbonyl]-5- LSD1 [(4-carbamimidoylpiperazin-1-yl)methyl]benzoate

H3K4me3 demethylase inhibitor, 2-[[[2-[2-(dimethylamino)ethyl-ethylamino]-2- LSD1 oxoethyl]amino]methyl]pyridine-4-carboxamide H3K4me3 demethylase inhibitor, LSD1 2-(4-methylphenyl)-1,2-benzothiazol-3-one H3K4me3 demethylase inhibitor, L^SD1 5-chloro-N-[(E)-[phenyl(pyridin-2-yl)methylidene]amino]pyridin-2-amine H3K4me3 demethylase inhibitor, LSD1 methyl 2-benzamido-1-(3-phenylpropyl)benzimidazole-5-carboxylate Histone deacetylase inhibitor 2-[(2-hydroxynaphthalen-1-yl)methylideneamino]-N-(1-phenylethyl)benzamide Histone deacetylase inhibitor 3-(prop-2-enyldisulfanyl)prop-1-ene Inhibit H3K9 methylation, N-(1-benzylpiperidin-4-yl)-6,7-dimethoxy-2-(4-methyl-1,4-diazepan- SDG21 1-yl)quinazolin-4-amine Inhibit H3K9 methylation, 5'-methoxy-6'-(3-pyrrolidin-1-ylpropoxy)spiro[cyclobutane-1,3'-indole]- SDG21 2'-amine Inhibit H3K9 methylation, 2-cyclohexyl-6-methoxy-N-(1-propan-2-ylpiperidin-4-yl)-7-(3-pyrrolidin- SDG21 1-ylpropoxy)quinazolin-4-amine Inhibit H3K9 methylation, 7-[3-(dimethylamino)propoxy]-6-methoxy-2-(4-methyl-1,4-diazepan-1-yl)- SDG21 N-(1-methylpiperidin-4-yl)quinazolin-4-amine Inhibit 14-(hydroxymethyl)-3-[14-(hydroxymethyl)-18-methyl-13,17-dioxo-15,16- H3K9 dithia-10,12,18-triazapentacyclo[12.2.2.01,12.03,11.04,9]octadeca-4,6,8- methylation, trien-3-yl]-18-methyl-15,16-dithia-10,12,18- SUVH4/5/6 triazapentacyclo[12.2.2.01,12.03,11.04,9]octadeca-4,6,8-triene-13,17-dione HSP90 2,3-dichloro-1,4-naphthoquinone HSP90 2,3-dichloro-5,8-dihydroxy-1,4-naphthoquinone HSP90 (1S,2R,4S)-1,7,7-trimethylbicyclo[2.2.1]heptan-2-ol HSP90 2-isothiocyanatoethylbenzene HSP90 4-isothiocyanatobutylbenzene HSP90 3-isothiocyanatoprop-1-ene HSP90 isothiocyanatoethane HSP90 1-isothiocyanatobutane HSP90 3-isothiocyanato-2-methylprop-1-ene [(4E,6Z,8S,9S,10E,12S,13R,14S,16R)-13-hydroxy-8,14,19- trimethoxy-4,10,12,16-tetramethyl-3,20,22-trioxo-2- HSP90 azabicyclo[16.3.1]docosa-1(21),4,6,10,18-pentaen-9-yl] carbamate 4-[[(2R,3S,4R,5R)-5-[6-amino-8-[(3,4-dichlorophenyl)methylamino]purin- HSP90 9-yl]-3,4-dihydroxyoxolan-2-yl]methoxymethyl]benzonitrile 24-methyl-5,7,18,20-tetraoxa-24- azoniahexacyclo[11.11.0.02,10.04,8.014,22.017,21]tetracosa- HSP90 1(24),2,4(8),9,11,13,15,17(21),22-nonaene HSP90 (4S)-4-prop-1-en-2-ylcyclohexene-1-carbaldehyde HSP90 (4R)-1-methyl-4-prop-1-en-2-ylcyclohexene HSP90 (1R,4R)-1,7,7-trimethylbicyclo[2.2.1]heptan-2-one HSP90 1,3,3-trimethyl-2-oxabicyclo[2.2.2]octane HSP90 2,6,6-trimethylbicyclo[3.1.1]hept-2-ene HSP90 isothiocyanatobenzene HSP90 2-isothiocyanatopropane HSP90 1-isothiocyanato-2-methylpropane HSP90 1-isothiocyanatohexane HSP90 1-isothiocyanato-4-methylsulfinylbutane HSP90 1-isothiocyanato-5-methylsulfinylpentane 8-[(6-iodo-1,3-benzodioxol-5-yl)sulfanyl]-9-[3-(propan-2- HSP90 ylamino)propyl]purin-6-amine [4-[2-carbamoyl-5-[6,6-dimethyl-4-oxo-3-(trifluoromethyl)- HSP90 5,7-dihydroindazol-1-yl]anilino]cyclohexyl] 2-aminoacetate 3-(2,4-dihydroxy-5-propan-2-ylphenyl)-4-(1-methylindol-5-yl)-1H- HSP90 1,2,4-triazol-5-one mimic cold ^stress N-acetyl-5-methoxytryptamine mimic pathogen ^stress S-methyl 1,2,3-benzothiadiazole-7-carbothioate mimic pathogen ^stress 5-chloro-2-methylpyrazole-3-carboxylic acid mimic pathogen stress 3-prop-2-enoxy-1,2-benzothiazole 1,1-dioxide mimic pathogen ^stress 3-aminobutanoic acid mimic pathogen stress 1,1-dioxo-1,2-benzothiazol-3-one mimic pathogen stress 4-hydroxybenzohydrazide mimic pathogen stress 3-hydroxy-3-(2-oxopropyl)-1H-indol-2-one mimic pathogen 2-[3-[(4-amino-2-methylpyrimidin-5-yl)methyl]-4-methyl-1,3-thiazol-3-ium- stress 5-yl]ethanol mimic pathogen stress 2,6-dichloropyridine-4-carboxylic acid mimic pathogen stress 3-Methoxybenzo[d]isothiazole 1,1-dioxide mimic pathogen stress N-(3-chloro-4-methylphenyl)-4-methylthiadiazole-5-carboxamide mimic pathogen ^stress 3,4-dichloro-N-(2-cyanophenyl)-1,2-thiazole-5-carboxamide mimic pathogen stress 2-Amino-3,5-dichlorobenzoic acid mimic pathogen stress 3-(furan-2-yl)-3-phenylpropan-1-amine mimic pathogen stress 4-amino-N-(5-methoxypyrimidin-2-yl)benzenesulfonamide mimic pathogen stress 4-amino-N-(6-methoxypyridazin-3-yl)benzenesulfonamide mimic N-(4-aminophenyl)sulfonylbenzamide pathogen stress mimic pathogen stress 4-amino-N-(6-chloropyridazin-3-yl)benzenesulfonamide mimic pathogen stress 4-amino-N-(5-methyl-1,2-oxazol-3-yl)benzenesulfonamide mimic pathogen stress 3-(butylamino)-4-phenoxy-5-sulfamoylbenzoic acid mimic pathogen 3-benzyl-1,1-dioxo-6-(trifluoromethyl)-3,4-dihydro-2H- stress 1^6,2,4-benzothiadiazine-7-sulfonamide mimic pathogen stress 4-chloro-N-[(2R,6S)-2,6-dimethylpiperidin-1-yl]-3-sulfamoylbenzamide mimic (3R,4S,5R,6R)-4-[(3R,4S,5R,6R)-3,5-dihydroxy-6-(hydroxymethyl)-4- pathogen [(3R,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyoxan- stress 2-yl]oxy-6-(hydroxymethyl)oxane-2,3,5-triol mimic pathogen (3R,6S)-3-hydroxy-3-[(3-hydroxyphenyl)methyl]-1,4-dimethyl-6-[(4-nitro- stress 1H-indol-3-yl)methyl]piperazine-2,5-dione mimic pathogen stress 2,4-dichloro-6-[(3-methoxyphenyl)iminomethyl]phenol mimic pathogen stress 1,2-benzothiazole 1,1-dioxide RECQ4A 5-[(3-carboxy-4-hydroxyphenyl)-(3-carboxy-4-oxocyclohexa-2,5-dien-1- (BLM) ylidene)methyl]-2-hydroxybenzoic acid RECQ4A disodium;6-methyl-2-[4-[2-[4-(6-methyl-7-sulfonato-1,3-benzothiazol- (BLM) 2-yl)phenyl]iminohydrazinyl]phenyl]-1,3-benzothiazole-7-sulfonate 8-[[4-methyl-3-[[3-[[3-[[2-methyl-5-[(4,6,8-trisulfonaphthalen-1- RECQ4A yl)carbamoyl]phenyl]carbamoyl]phenyl]carbamoylamino]benzoyl]amino]benz (BLM) oyl]amino]naphthalene-1,3,5-trisulfonic acid RECQ4A 1-[4-Fluoro-3-(trifluoromethyl)phenyl]-3-(5-pyridin-4-yl-1,3,4-thiadiazol- (BLM) 2-yl)urea RECQ4A 3-[18-(2-carboxyethyl)-7,12-diethyl-3,8,13,17,22-pentamethyl-23H- (BLM) porphyrin-2-yl]propanoic acid RECQ4A 1h-pyrrole-2,5-dione, 1-[(1-oxopropoxy)methyl]-N- (BLM) propionyloxymethyl-maleimide RECQ4A 3,4-dichloro-1-[3-(3,4-dichloro-2,5-dioxopyrrol-1-yl)-2,2- (BLM) dimethylpropyl]pyrrole-2,5-dione 5,7-dioxa-12-azoniapentacyclo[10.6.1.02,10.04,8.015,19]nonadeca- TOP3A 1(18),2,4(8),9,11,15(19),16-heptaen-17-ol DNA ligase IV 5,6-bis(((E)-benzylidene)amino)-2-thioxo-2,3-dihydropyrimidin-4(1H)-one allelopathic (6Z)-3,7,11-trimethyldodeca-1,6,10-trien-3-ol allelopathic (2S,5R)-5-methyl-2-propan-2-ylcyclohexan-1-one (1S,2S,5S,8R,9S,10S,11R,15S,18R)-9,10,15,18-tetrahydroxy-12,12-dimethyl- allelopathic 6-methylidene-17-oxapentacyclo[7.6.2.15,8.01,11.02,8]octadecan-7-one (1R,2R,5R,9R,12R,16R)-5-ethenyl-1,5,12-trimethyl-10- allelopathic oxatetracyclo[7.6.1.02,7.012,16]hexadec-7-ene-11,13-dione (1S,2R,5R,12R,18R)-5-ethenyl-13-hydroxy-5,12-dimethyl-10,14- allelopathic dioxapentacyclo[11.2.2.11,9.02,7.012,18]octadec-7-en-11-one [(1R,2R,4S,6S,9R,10S,13S,16R)-2,16-dihydroxy-5,5,9-trimethyl-14- allelopathic methylidene-15-oxo-6-tetracyclo[11.2.1.01,10.04,9]hexadecanyl] acetate (1S,4S,8R,9R,12S,13S,14S,16S)-9,14-dihydroxy-7,7-dimethyl-17-methylidene- allelopathic 3,10-dioxapentacyclo[14.2.1.01,13.04,12.08,12]nonadecane-2,18-dione [(1S,1'R,3'S,5R,6S,7S,9S)-3'-acetyloxy-7-hydroxy-6',6'-dimethyl- 10-methylidene-2,11-dioxospiro[3-oxatricyclo[7.2.1.01,6]dodecane- allelopathic 5,2'-cyclohexane]-1'-yl]methyl acetate allelopathic (3E,6E)-3,7,11-trimethyldodeca-1,3,6,10-tetraene allelopathic 6,6-dimethyl-2-methylidenebicyclo[3.1.1]heptane allelopathic 2,2-dimethyl-3-methylidenebicyclo[2.2.1]heptane allelopathic 5-methyl-2-propan-2-ylphenol allelopathic (2E)-3,7-dimethylocta-2,6-dien-1-ol allelopathic (2E)-3,7-dimethylocta-2,6-dienal allelopathic 5-methyl-2-propan-2-ylcyclohexan-1-ol allelopathic benzoic acid allelopathic 2-aminophenoxazin-3-one allelopathic 2-amino-7-methoxyphenoxazin-3-one allelopathic (2S,3R)-2-(3,4-dihydroxyphenyl)-3,4-dihydro-2H-chromene-3,5,7-triol [0041] In some embodiments, the compound that modulates meiotic recombination is selected from the group consisting of 3-aminobutanoic acid, 2-isothiocyanatoethylbenzene, N-(1-benzylpiperidin-4-yl)- 6,7-dimethoxy-2-(4-methyl-1,4-diazepan-1-yl)quinazolin-4-amine, 3-Chloro-2-{(Z)-(4-chlorophenyl)[(6- chloro-2-pyridinyl)hydrazono]methyl}-5-(trifluoromethyl)pyridine, 4-allyl-5-{[(2- nitrophenyl)thio]methyl}-4H-1,2,4-triazole-3-thiol, 4-hydroxybenzohydrazide, 5-chloro-N-[(E)- [phenyl(pyridin-2-yl)methylidene]amino]pyridin-2-amine, 4-amino-1-[(2R,4S,5R)-4-hydroxy-5- (hydroxymethyl)oxolan-2-yl]-1,3,5-triazin-2-one, 3-[4-[(1R,2S)-2-aminocyclopropyl]phenyl]phenol, [(1S,2S,4R)-4-[4-[[(1S)-2,3-dihydro-1H-inden-1-yl]amino]pyrrolo[2,3-d]pyrimidin-7-yl]-2- hydroxycyclopentyl]methyl sulfamate, (4R)-1-methyl-4-prop-1-en-2-ylcyclohexene, S-methyl 1,2,3- benzothiadiazole-7-carbothioate, (1R,4R)-1,7,7-trimethylbicyclo[2.2.1]heptan-2-one, 4- isothiocyanatobutylbenzene, ylamino)propyl]purin-6-amine, 1-isothiocyanatobutane, 5-methyl-2-propan- 2-ylphenol, 5'-methoxy-6'-(3-pyrrolidin-1-ylpropoxy)spiro[cyclobutane-1,3'-indole]-2'-amine, 6,6- dimethyl-2-methylidenebicyclo[3.1.1]heptane, 5,7-dihydroxy-3-(4-hydroxyphenyl)chromen-4-one, disodium;6-methyl-2-[4-[2-[4-(6-methyl-7-sulfonato-1,3-benzothiazol-2- yl)phenyl]iminohydrazinyl]phenyl]-1,3-benzothiazole-7-sulfonate, methyl 2-benzamido-1-(3- phenylpropyl)benzimidazole-5-carboxylate, 4-amino-N-(5-methyl-1,2-oxazol-3-yl)benzenesulfonamide, 3-(furan-2-yl)-3-phenylpropan-1-amine, 1-isothiocyanato-2-methylpropane, 2-Amino-3,5-dichlorobenzoic acid, isothiocyanatoethane, 3-Methoxybenzo[d]isothiazole 1,1-dioxide, 8-[[4-methyl-3-[[3-[[3-[[2-methyl- 5-[(4,6,8-trisulfonaphthalen-1- yl)carbamoyl]phenyl]carbamoyl]phenyl]carbamoylamino]benzoyl]amino]benzoyl]amino]naphthalene- 1,3,5-trisulfonic acid, 7-[3-(dimethylamino)propoxy]-6-methoxy-2-(4-methyl-1,4-diazepan-1-yl)-N-(1- methylpiperidin-4-yl)quinazolin-4-amine, N-(3-chloro-4-methylphenyl)-4-methylthiadiazole-5- carboxamide, 8-[(6-iodo-1,3-benzodioxol-5-yl)sulfanyl]-9-[3-(propan-2-(3R,4S,5R,6R)-4- [(3R,4S,5R,6R)-3,5-dihydroxy-6-(hydroxymethyl)-4-[(3R,4S,5S,6R)-3,4,5-trihydroxy-6- (hydroxymethyl)oxan-2-yl]oxyoxan-2-yl]oxy-6-(hydroxymethyl)oxane-2,3,5-triol, 4-amino-1- [(2R,3R,4S,5R)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]-1,3,5-triazin-2-one, 1- isothiocyanatohexane, (2E,4E,6R)-7-[4-(dimethylamino)phenyl]-N-hydroxy-4,6-dimethyl-7-oxohepta- 2,4-dienamide, 2,2,2-trifluoroethyl N-[(2S)-3-methyl-1-[(4-methylbenzoyl)amino]butan-2-yl]carbamate, 4-amino-N-(4,6-dimethylpyrimidin-2-yl)benzenesulfonamide, 4-amino-N-(6-methoxypyridazin-3- yl)benzenesulfonamide, 2-cyclohexyl-6-methoxy-N-(1-propan-2-ylpiperidin-4-yl)-7-(3-pyrrolidin-1- ylpropoxy)quinazolin-4-amine, 4-amino-N-(5-methoxypyrimidin-2-yl)benzenesulfonamide, HB2, 2-[2- (3,4-dimethoxyphenyl)ethylamino]-6-(3-fluorophenyl)-8H-pyrimido[4,5-d]pyrimidine-5,7-dione, FN3, 4- amino-N-(6-chloropyridazin-3-yl)benzenesulfonamide, 1-(4-((dimethylamino)methyl)phenyl)-8,9- dihydro-2,7,9a-triazabenzo[cd]azulen-6(7H)-one, 7-[3-(dimethylamino)propoxy]-6-methoxy-2-(4-methyl- 1,4-diazepan-1-yl)-N-(1-methylpiperidin-4-yl)quinazolin-4-amine, azane;dichloroplatinum(2+), 3,5- dichloro-N-(2-methylbut-3-yn-2-yl)benzamide, 4-[(E)-2-(3,5-dimethoxyphenyl)ethenyl]phenol, PS27, (2E)-3,7-dimethylocta-2,6-dien-1-ol, 2,2-dimethyl-3-methylidenebicyclo[2.2.1]heptane, and (2S,5R)-5- methyl-2-propan-2-ylcyclohexan-1-one. [0042] In some embodiments, the compound that modulates meiotic recombination is selected from the group consisting of tolprocarb, 4-allyl-5-{[(2-nitrophenyl)thio]methyl}-4H-1,2,4-triazole-3-thiol, 4- [(E)-2-(2-Quinolinyl)vinyl]phenol, 9-(2,3-Dihydroxypropyl)-adenine, 2,2-Dichloro-N-[(1R)-1-(4- chlorophenyl)ethyl]-1-ethyl-3-methylcyclopropanecarboxamide, 2,2-Dichloro-3,3- dimethylcyclopropanecarboxylic acid, and 3-methyl-2-[(Z)-pent-2-enyl]cyclopent-2-en-1-one. [0043] In some embodiments, the compound that modulates meiotic recombination is selected from the group consisting of propyzamide, 3-Chloro-2-{(2E)-2-[phenyl(2-pyridinyl)methylene]hydrazino}-5- (trifluoromethyl)pyridine, 4-[2-(3,5-Dimethyl-2-oxocyclohexyl)-2-hydroxyethyl]-2,6-piperidi, trifluralin, Caffeine, 1-(Ethylamino)-1-oxo-2-propanyl phenylcarbamate, and 3-Chloro-2-{(Z)-(4-chlorophenyl)[(6- chloro-2-pyridinyl)hydrazono]methyl}-5-(trifluoromethyl)pyridine. [0044] In some embodiments, the compound that modulates meiotic recombination is 4-allyl-5-{[(2- nitrophenyl)thio]methyl}-4H-1,2,4-triazole-3-thiol or 3-Chloro-2-{(Z)-(4-chlorophenyl)[(6-chloro-2- pyridinyl)hydrazono]methyl}-5-(trifluoromethyl)pyridine. [0045] In some embodiments, the compound that modulates meiotic recombination is 3-aminobutanoic acid or 2-isothiocyanatoethylbenzene. [0046] In some embodiments, a method of the present invention improves linkage drag in a plant and/or its progeny such as by reducing linkage drag. During plant breeding desirable traits controlled by versions of genes (alleles) at genetic loci are selected for inclusion in elite commercial lines. Desirable trait loci can be located near (genetically linked) loci with alleles that impart undesirable traits. As a result, selecting the desirable trait, can "drag" the undesirable trait along with the desirable trait during breeding cycles. Separation of desirable traits from undesirable traits occurs when the DNA between the loci recombines (also known as a genetic exchange, or crossing-over) during meiosis. However, several factors limit the ability of crossovers to disrupt linkage drag. The number of crossovers a genome experiences in each meiosis is limited. In addition, the probability that a crossover occurs between two loci in inversely proportional to their distance from one another. To overcome these limitations breeders will use costly, time-intensive, labor-intensive and space-intensive strategies to screen though large populations to find the desired combination of alleles (genotypes). In some embodiments, by applying to a plant a compound of the present invention that increases meiotic recombination in the plant, linkage drag may be reduced [0047] In some embodiments, a method of the present invention increases recombination in a cold region (e.g., dead zone) of a plant genome. Crossovers are not distributed evenly across the genome during meiosis. Instead, there are crossover hotspots, crossover coldspots and regions that rarely if ever experience crossovers. Hotspots and coldspots (e.g., cold regions) are defined as regions of the genome that experience a statistically higher or lower, respectively, frequency of crossovers when compared to the genomic average for a given genotype (species, line, accession) in a given set of growth conditions. Alleles at loci in recombination cold/dead regions experience significantly fewer recombination events compared to the genomic average and as a result fewer new combinations of alleles (genotypes) are generated during meiosis. Plant breeders view these regions as a potentially rich source for "hidden" genetic variation - hidden in the sense that if recombination could be induced in these regions, novel genotypes with desirable phenotypes could be created. In some embodiments, by applying to a plant a compound of the present invention that increases meiotic recombination in the plant, an increase in recombination in a cold region may be achieved and/or hidden variation may be revealed. [0048] In some embodiments, a method of the present invention eliminates the need for back crossing or decreases the amount of time for back crossing for a plant and/or its progeny. A method of the present invention may be devoid of a back crossing step. In some embodiments, a method of the present invention may reduce the number of backcross generations in a plant breeding method. During plant breeding experimental or wild accessions can be crossed with elite commercial lines to transfer desirable traits from the former into the latter via a process called introgression. Progeny from these crosses are then backcrossed to the elite parent to restore the elite parental genotype, reduce the experimental/wild genotype, and maintain the desirable trait. The efficiency of maximizing restoration of the elite genotype, and minimizing the experimental/wild genotype while maintaining the desirable trait is dependent on the frequency of meiotic recombination. To overcome limited meiotic recombination, plant breeders typically use several backcross generations which is costly, time-intensive, labor-intensive and space-intensive. In some embodiments, by applying to a plant a compound of the present invention that increases meiotic recombination in plants, the number of backcrossing generations could be reduced or eliminated in a plant breeding method. [0049] In some embodiments, the plant in a method of the present invention is a crop plant (e.g., corn, tomato, soybean, wheat, oilseed plant, etc.). In some embodiments, the plant in a method of the present invention is a monocot. In some embodiments, the plant in a method of the present invention is a eudicot. Non-limiting examples of plants useful with the present invention include turf grasses (e.g., bluegrass, bentgrass, ryegrass, fescue), feather reed grass, tufted hair grass, miscanthus, arundo, switchgrass, vegetable crops, including artichokes, kohlrabi, arugula, leeks, asparagus, lettuce (e.g., head, leaf, romaine), malanga, melons (e.g., muskmelon, watermelon, crenshaw, honeydew, cantaloupe), cole crops (e.g., brussels sprouts, cabbage, cauliflower, broccoli, collards, kale, Chinese cabbage, bok choy), cardoni, carrots, napa, okra, onions, celery, parsley, chick peas, parsnips, chicory, peppers, potatoes, cucurbits (e.g., marrow, cucumber, zucchini, squash, pumpkin, honeydew melon, watermelon, cantaloupe), radishes, dry bulb onions, rutabaga, eggplant, salsify, escarole, shallots, endive, garlic, spinach, green onions, squash, greens, beet (sugar beet and fodder beet), sweet potatoes, chard, horseradish, tomatoes, turnips, and spices; a fruit crop such as apples, apricots, cherries, nectarines, peaches, pears, plums, prunes, cherry, quince, fig, nuts (e.g., chestnuts, pecans, pistachios, hazelnuts, pistachios, peanuts, walnuts, macadamia nuts, almonds, and the like), citrus (e.g., clementine, kumquat, orange, grapefruit, tangerine, mandarin, lemon, lime, and the like), blueberries, black raspberries, boysenberries, cranberries, currants, gooseberries, loganberries, raspberries, strawberries, blackberries, grapes (wine and table), avocados, bananas, kiwi, persimmons, pomegranate, pineapple, tropical fruits, pomes, melon, mango, papaya, and lychee, a field crop plant such as clover, alfalfa, timothy, evening primrose, meadow foam, corn/maize (field, sweet, popcorn), hops, jojoba, buckwheat, safflower, quinoa, wheat, rice, barley, rye, millet, sorghum, oats, triticale, sorghum, tobacco, kapok, a leguminous plant (beans (e.g., green and dried), lentils, peas, soybeans), an oil plant (rape, canola, mustard, poppy, olive, sunflower, coconut, castor oil plant, cocoa bean, groundnut, oil palm), duckweed, Arabidopsis, a fiber plant (cotton, flax, hemp, jute), Cannabis (e.g., Cannabis sativa,Cannabis indica, and Cannabis ruderalis), lauraceae (cinnamon, camphor), or a plant such as coffee, sugar cane, tea, and natural rubber plants; and/or a bedding plant such as a flowering plant, a cactus, a succulent and/or an ornamental plant (e.g., roses, tulips, violets), as well as trees such as forest trees (broad-leaved trees and evergreens, such as conifers; e.g., elm, ash, oak, maple, fir, spruce, cedar, pine, birch, cypress, eucalyptus, willow), as well as shrubs and other nursery stock. [0050] Delivery systems [0051] Compounds having the ability to impact meiotic recombination, hereinafter also referred to as active ingredients or actives, are usually applied in the form of a dilute aqueous preparation in order to achieve a good interaction with the target organisms, such as plants. However, active ingredients might be sparingly or even insoluble in water, i.e. they usually have a water-solubility of not more than 5 g/l, often not more than 1 g/l and particularly not more than 0.1 g/l at 25°C/1013 mbar. Therefore, formulators are often confronted with difficulties in formulating active ingredients in stable formulations that can be easily diluted with water and that deliver maximum loading of the active ingredient per unit volume to the end user. [0052] A compound that modulates meiotic recombination may be present in a composition (e.g., an aqueous composition). The compound may be present in the composition in an amount of about 0.001, 0.01, 0.05, 0.1, 0.5, 1, 1.5, 2, 2.5, 3, 4, or 5 mM to about 6, 7, 8, 9, 10, 11, 12, 13 ,14, 15, 16, 17, 18, 19, 20, 25, 30, 35, or 40 mM. In some embodiments, the compound may be present in the composition in an amount of about 0.001, 0.01, 0.05, 0.1, 0.5, 1, 1.5, 2, 2.5, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13 ,14, 15, 16, 17, 18, 19, 20, 25, 30, 35, or 40 mM. [0053] In some embodiments, the composition comprises water and/or dimethylsulfoxide (DMSO). DMSO may be present in a composition in an amount of about 0.001% to about 10% by weight and/or by v/v of the composition. A composition comprising a compound that modulates meiotic recombination may also include a surfactant such as, but not limited to, Tween-20 and/or Silwet, optionally at a concentration of about 0.025% to about 0.25% v/v of the composition. In some embodiments, inclusion of DMSO and/or a surfactant may enhance delivery of the compound that modulates meiotic recombination to the plant. [0054] In some embodiments, the composition comprises wherein the composition comprises at least two emulsifiers, at least two adjuvants and at least two carriers. In some embodiments, the composition comprises three adjuvants. [0055] There are several approaches to preparing concentrated formulations with active ingredient compounds having limited water solubility, including solid formulations, such as wettablye dispersible granule (WDG’s) oder wettable powders (WPD’s), and liquid formulations such as suspension concentrates (SC’s) and supsoemulsion concentrates (SEC’s), emulsifyables (EC’s) and emulsions (EW’s). [0004] Suspension concentrates are liquid formulations, wherein the active ingredient is present in the form of finely divided solid particles, which are suspended in an aqueous dispersing medium utilizing surface- active compounds, such as wetting agents, dispersants and rheological or suspending aids for stabilising the active ingredient particles in the dispersing medium. In SC’s, the particles of the active ingredient usually have particle sizes in the range of 1 to 20 mm. Even smaller particle sizes, i.e. < 1 mm, e.g.0.5 to < 1 mm, can be obtained by elaborate grinding techniques. However, problems are often encountered with SC’s as a result of settling during prolonged storage or storage at elevated temperatures, the resistance of settled particles to resuspension and the formation of crystalline material upon storage. As a consequence, the formulations are difficult to handle and the bioefficacy may be inconsistent. Moreover, since the particle size of the active ingredient particles is large in SC’s, they may often result in a lower efficacy. Suspoemulsion concentrates are similar to suspension concentrates, however they additionally contain solution of the active in a water-immiscible solvent, the solution being present in the form of small droplets which are emulsified in the aqueos phase. Due to the presence of three phases, SEC’s are often instable. Moreover, SEC’s contain noticeable amounts of water-immiscible organic solvents, which are not entirely satisfactory with regard to their ecological and toxicological properties. [0056] In an EC, the active ingredient is dissolved in a water-immiscible solvent (solubility usually < 0:1 g/l), frequently in hydrocarbon solvents including aromatic hydrocarbons, together with surfactants. Generally, EC’s are stable solutions that can be diluted with water to form a milky oil-in-water emulsion, containing the active ingredient dissolved in the solvent droplets. EC formulations have a considerable drawback in that they contain considerable amounts of volatile organic solvents which are not entirely satisfactory with regard to their ecological and toxicological properties. Moreover, EC’s are limited to active ingredient compounds which are soluble in water-immiscible solvents. As a result of the large particle size of the solvents droplets, the bioefficacy of the active ingredient is sometimes not satisfactory. [0057] In an EW, a liquid active ingredient is emulsified in water by means of surfactant. Upon dilution with water the EW’s overcome some of the drawbacks associated with EC’s, since they contain no solvents, or only small amounts. On the other hand, they are limited to liquid active ingredients which must also be stable to hydrolysis. [0058] The term "surfactant" as used herein is well known in the art and includes any organic substance which is capable of reducing the surface tension of a phase boundary between an organic phase and an aqeuos phase. Suitable surfactants include non-polymeric surfactants and polymeric surfactants. The term "non-polymeric surfactant" relates to surface active compounds having an molecular weight below 1000 Dalton, in particular below 800 Dalton (number average), while the term "polymeric surfactant" relates to surface active substances having an molecular weight exceeding 1000 Dalton (number average). The surfactant usually make up from 5 to 90% by weight, frequently from 10 to 80% by weight, preferably from 15 to 50% by weight and in particular from 20 to 50% by weight, based on the total weight of the formulation according to the invention. The weight ratio of surfactant S to active ingredient compound C is frequently from 0.6:1 to 10:1, preferably from 0.8:1 to 5:1 more preferably from 0.9:1 to 4:1, and in particular from 1:1 to 3:1. [0059] The surfactants may be non-ionic, anionic, cationic or amphoteric. Suitable surfactants that may be contained in the liquid formulations of the invention are disclosed, e.g. in "McCutcheon’s Detergents and Emulsifiers Annual", MC Publishing Corp., Ridgewood, NJ, USA 1981; H. Stache, "Tensid- Taschenbuch", 2nd ed., C. Hanser, Munich, Vienna, 1981; M. and J. Ash, "Encyclopedia of Surfactants", vol. I-III, Chemical Publishing Co.; New York, NY, USA 1980-1981. [0049] Examples of non-polymeric surfactants comprise - anionic non-polymeric surfactants, selected from the salts, in particular the sodium, potassium calcium or ammonium salts of - alkylsulfonates, such as lauryl sulfonate, isotridecylsulfonate, - alkylsulfates, in particular fatty alcohol sulfates, such as lauryl sulfate, isotridecylsulfate, cetylsulfate, stearyl[1]sulfate - aryl- and alkylarylsulfonates, such as napthylsulfonate, dibutyinaphtylsulfonate, alkyldiphenylether sulfonates such as dodecyldiphenylether sulfonate, alkylbenzene sulfonates such as cumylsulfonate, nonylbenzenesul-fonate and dodecylbenzene sulfonate; - sulfonates of fatty acids and fatty acid esters; - sulfates of fatty acids and fatty acid esters; - sulfates of ethoxylated alkanoles, such as sulfates of ethoxylated lauryl alcohol; - sulfates of alkoxylated alkylphenols; - alkylphosphates, in particular C8- C16 alkylphosphates; - dialkylphosphates, in particular C8-C16 dialkylphosphates; - dialkylesters of sulfosuccinic acid, such as dioctylsulfosuccinate, - acylsarcosinates, - fatty acids, such as stearates, - acylglutamates, - ligninsulfonates, - low molecular weight condensates of naphthalinesulfonic acid or phenolsulfonic acid with formaldehyde and optionally urea; - non-ionic non-polymeric surfactants, selected from the group of - ethoxylated alkanoles, in particular ethoxylated fatty alcohols and ethoxylated oxoalcohols, such as ethoxylated lauryl alcohol, ethoxylated isotridecanol, ethoxylated cetyl alcohol, ethoxylated stearyl alcohol, and esters there[1]of, such as acetates - ethoxylated alkylphenols, such as ethoxylated nonylphenyl, ethoxylated dodecylphenyl, ethoxylated isotride[1]cylphenol and the esters thereof, e.g. the acetates - alkylglucosides and alkyl polygucosides, - ethoxylated alkylglucosides, - ethoxylated fatty amines, - ethoxylated fatty acids, - partial esters, such as mono-, di- and triesters of fatty acids with glycerine or sorbitan, such as glycerine mon[1]ostearate, glycerine monooleate, sorbitanmonolaurate, sorbitanmonopalmitate, sorbitanmonostearate, sorbitan monooleate, sorbitantristearate, sorbitan trioleate; - ethoxylated esters of fatty acids with glycerine or sorbitan, such as polyoxyethylene glycerine monostearate, polyoxyethylene sorbitanmonolaurate, sorbitanmonopalmitate, polyoxyethylene sorbitanmonostearate, polyox-ethhylene sorbitan monooleate, polyoxyethylene sorbitantristearate, polyoxyethylene sorbitan trioleate; EP 1973401 B1, ethoxylates of vegetable oils or animal fats, such as corn oil ethoxylate, castor oil ethoxylate, tallow oil ethoxylate, - ethoxylates of fatty amines, fatty amides or of fatty acid diethanolamides - cationic non-polymeric surfactants, selected from the group of - quaternary ammonium compounds, in particular alkyltrimethylammonium salts and dialkyldimethylammonium salts, e.g. the halides, sulfates and alkylsulfates - Pyridinium salts, in particular alkylpyridinium salts e.g. the halides, sulfates and C1-C4-alkylsulfates and - Imidazolinium salts in particular N,N’-dialkylimidazolinium salts, e.g. the halides, sulfates or methoxulfates. [0060] As regards the non-polymeric surfactants, the term "alkyl" as used herein and if not defined otherwise is a linear or branched alkyl group having from 4 to 30, preferably from 6 to 22 carbon atoms, e.g. n-hexyl, 1-methylpentyl, n-heptyl, n-octyl, 2-ethylhexyl, n-nonyl, n-decyl, 1-methylnonyl, 2- propylheptyl, n-dodecyl, 1-methyldodecyl, n-tridecyl, n-tetrade[1]cyl, n-pentadecyl, n-hexadecyl, n- heptadecyl, n-octadecyl, n-nonadecyl, n-eicosyl, and the like. Likewise, the terms "fatty acid", "fatty alcohol", "fatty amine" and "fatty amide" refer to alkanoic acids, alkanols, alkylamines or alkanoic amides having from 6 to 30, in particular from 8 to 22 carbon atoms and wherein the saturated alkyl radical may be linear or branched. The terms "ethoxylated", "polyoxyalkylene" or "polyoxyethylene", respectively, mean that OH-functions have been reacted with ethyleneoxide or C2-C4-alkylene oxide to form a oligoalkylen oxide (= polyoxyalkylene) or oligoethyl[1]eneoxide (= polyoxyethylene) group. The degree of alkoxylation or ethoxylation (number average of alkylene oxide or ethyleneoxide repeating units) will usually be in the range from 1 to 50 and in particular from 2 to 40 more preferably from 2 to 30. [0061] Examples of polymeric surfactants include - anionic polymers having anionic groups such as carboxylate groups or sulfonate groups and lipophilic moieties, e.g. the salts of copolymers of monoethylenically unsaturated carboxylic acids, such as acrylic acid or methacrylic acid, with monoethylenically hydrocarbons, such as styrene, or C2-C18 olefines, salts of copolymers of monoethylenically unsaturated sulfonic acids with alkylacrylates or methacrylates. - non-ionic polymers having polyether moieties such as poly-C2-C10-alkyleneethers containing polymerized units derived from ethylene oxide and polymerized units derived from C3-C10-alkylene oxides, in particular blockcopoly[1]mers comprising at least one polyethyleneoxide moiety PEO and at least one polyether moiety PAO (hereinafter also termed hydrophobic polyether moiety PAO) consisting of repeating units selected from C3-C10-alkylene oxides and styrene oxide, - cationic polymers having protonized or quaternized amino groups such as protonated polyalkylene imines, proto[1]nated or quaternized homo or copolymers of vinylpyridines, protonated or quaternized homo or copolymers of vinylimidazole. [0052] Preferably, the surfactant S or the mixture of surfactants S, which is contained in the formulation of the present invention, has a HLB-value ranging from 5 to 20 and in particular from 7 to 18, more preferably from 9 to 16. The HLB value (hydrophilic lipophilic balance) is an empirical quantity, which measures of the polarity of a surfactant or mixture of surfactants (see P. Becher et al, Non-ionic surfactants, Physical Chemistry, Marcel Dekker, N.Y. (1987), pp.439-456). [0062] Non-ionic surfactants are preferably selected from ethoxylated alkanols, sorbitan esters of fatty acids, polyoxyethylene sorbitan esters of fatty acids, alkyl glucosides , alkyl polyglucosides, polyoxyethylene alkyl glucosides, ethoxylated fatty amines, ethoxylated fatty acids and ethoxylated esters of fatty acids with glycerine. [0063] Non-ionic blockcopolymers P are known in the art and commercially available under the trade names Pluronic®, such as Pluronic® P 65, P84, P 103, P 105, P 123 and Pluronic® L 31, L 43, L 62, L 62 LF, L 64, L 81, L 92 and L 121, Pluraflo® such as Pluraflo® L 860, L1030 and L 1060Tetronic®, such as Tetronic® 704, 709, 1104, 1304, 702, 1102, 1302, 701, 901, 1101, 1301 (BASF Aktiengesellschaft), Agrilan® AEC 167 and Agrilan® AEC 178 (Akcros Chemicals), Antarox® B/848 (Rhodia), Berol® 370 and Berol® 374 (Akzo Nobel Surface Chemistry), Dowfax® 50 C15, 63 N10, 63 N30, 64 N40 and 81 N10 (DowEurope), Genapol® PF (Clariant), Monolan®, such as Monolan® PB, Monolan® PC, Monolan® PK (Akcros Chemicals), Panox® PE (Pan Asian Chemical Corporation), Symperonic®, such as Symperonic® PE/L, Symperonic® PE/F, Symperonic® PE/P, Symperonic® PE/T (ICI Surfactants), Tergitol® XD, Tergitol® XH and Tergitol® XJ (Union Carbide), Triton@ CF-32 (Union Carbide), Teric PE Series (Huntsman) and Witconol®, such as Witconol® APEB, Witconol® NS 500 K and the like. [0064] Delivery formulation described herein may further contain customary auxiliaries, such as defoamers, thickeners, preservatives; colorants, stabilizers, adjuvants, wetting agents, penetrants, coupling agents and the like which are usually employed in non-aqueous formulations of active ingredients. A skilled person will appreciate that some of the aforementioned components, e.g. surfactants and solvents, may also work as auxiliaries. In particular, solvents may work as antifreeze agents or penetrants and the aforementioned surfactants may work as adjuvants or wetting agents. [0072] Suitable thickening agents include inorganic thickening agents, such as clays, hydrated magnesium silicates and organic thickening agents, such as polysaccharide gums, like xanthan gum, guar gum, gum arabic and cellulose derivatives. Organic thickening agents are employed in amounts of from 0.5 to 30 g/l and preferably from 1 to 10 g/l while inorganic thickening agents are employed in amounts of from 0.5 to 30 g/l and preferably from 1 to 10 g/l. [0073] Suitable preservatives to prevent microbial spoiling of the formulations of the invention include formaldehyde, alkyl esters of p-hydroxybenzoic acid, sodium benzoate, 2-bromo-2-nitropropane- 1,3-diol, o-phenylphenol, thia[1]zolinones, such as benzisothiazolinone, 5-chloro-2-methyl-4- isothiazolinone, pentachlorophenol, 2,4-dichlorobenzyl al[1]cohol and mixtures thereof. In general, the amount of preservatives will be from 0.1 to 10 g/l. [0074] Suitable defoamers include polysiloxanes, such as polydimethyl siloxane. Defoamers are usually employed in amounts of from 0.1 to 5 g/l: EP 1973401 B114510152025303540455055 Suitable stabilizers comprise e.g. UV-absorbers such as cinnamic esters, 3,3-diphenyl-2-cyano acrylates, hydroxy and/or alkoxy substituted benzophenones, N- (hydroxyphenyl)-benzotriazoles, hydroxyphenyl-s-triazines, oxalic amides and salicylates, e.g. the UVINUL® 3000, 3008, 3040, 3048, 3049, 3050, 3030, 3035, 3039, 3088, UVINUL® MC80 and radical scavengers, e.g. ascorbic acid, sterically hindered amines (HALS-compounds) such as UVINUL® 4049H, 4050H and 5050H, and the like and anti-oxidants such as vitamin E. In general, the amount of stabilizer will be from 0.01 to 10 g/l of the concentrate formulation. [0065] These customary auxiliaries may be contained within the formulation. However, it is also possible to add these auxiliaries after dilution with water to the ready-to-use aqueous formulation. Upon dilution with water, the liquid formulations of the invention form an aqueous active ingredient preparation which contains the at least one organic active ingredient compound C, the at least one organic solvent S, the at least one surfactant S and water. In these preparations, the at least one organic active ingredient compound is present in the form of finely divided particles having a particle size in the nm range, i.e. the average particle size as determined by dynamic light scattering (at 25°C and 1,013 mbar) is below 500 nm, preferably in the range from 100 to 300 nm, in particular in the range from 10 to 200 nm and most preferably in the range from 10 to 100 nm. In order to obtain these aqueous active ingredient preparations, the liquid formulations of the invention are usually diluted with at least 5 parts of water, preferably at least 10 parts of water, in particular at least 20 parts of water and more preferably at least 50 parts of water, e.g. from 10 to 10,000, in particular from 20 to 1,000 and more preferably from 50 to 250 parts of water per one part of the liquid formulation (all parts are given in parts by weight). [0066] Dilution will be usually achieved by pouring the concentrate formulation of the invention into water. Usually, dilution is achieved with agitation, e.g. with stirring, to ensure a rapid mixing of the concentrate in water. However, agitation is not necessary. Though the temperature of mixing is not critical, mixing is usually performed at temperatures ranging from 0 to 100°C, in particular from 10 to 50°C or at ambient temperature. The water used for mixing is usually tap water. However the water may already contain water soluble compounds which are used in plant protection, e.g. nutrificants, fertilizers or water soluble pesticides. [0067] The invention will now be described with reference to the following examples. It should be appreciated that these examples are not intended to limit the scope of the claims to the invention. but are rather intended to be exemplary of certain embodiments. Any variations in the exemplified methods that occur to the skilled artisan are intended to fall within the scope of the invention. EXAMPLES Example 1 [0068] An active ingredient (AI) (e.g., a compound that modulates meiotic recombination in a plant) was be applied to Arabidopsis plants using foliar spray, soil drench, or liquid media. The delivery of active ingredients was tested using two different emulsifiable concentrates using the following protocol: The active ingredient was dissolved in 100% DMSO. The emulsifiable concentrate system was added to water and mixed. Then, the compound/active ingredient was dissolved in DMSO and the emulsifiable concentrate and water dilution were mixed to achieve the desired final active ingredient final concentration. In this test system, the final concentration of DMSO is no higher than 10% (v/v) and the final concentration of EM system is no higher than 0.1%. The final system was applied to plants via spraying. [0069] An AI that increased or decreased meiotic recombination in an Arabidopsis plant was validated by applying the AI to tomato plants and scoring the respective meiotic crossover frequencies. A visual fluorescent pollen transgene assay (e.g., a tomato-based version of the FTL system as described in Francis et al., Proc Natl Acad Sci USA.2007; 104(10):3913-3918, Modliszewski et al., PLoS Genet, 2018, 14(5): e1007384, and/or Berchowitz, L. and Copenhaver, G. Nature Protocols, 2008; 3(1), 41-50) was used to measure meiotic crossover (CO) frequency. Post-treatment pollen viability was also assayed using a modified Alexander’s staining procedure. [0070] Success was defined as identification of one or more AIs that statistically increase or decrease meiotic CO frequency in treated plants compared to untreated controls at a significance level of p ^ 0.05. An increase in CO frequency by 3X or more is viewed as useful of breeding purposes. [0071] Crossovers was measured in pollen tetrads from replicate treated plants and compared to untreated or mock treated controls. Scoring as few as about 300 tetrads per treated plant or control was sufficient to detect modified (e.g., enhanced) crossover frequencies. Initially, each AI was tested at 100 ^M, 1 mM and 10 mM concentrations. If phytotoxicity for an AI was observed, then lower concentrations were tested. For some AIs, a finer resolution of concentrations was tested to develop a response curve. [0072] All chemicals (10 mM, 5 mM, 7.5 mM 1 mM, 0.1 mM) were initially screened using visual markers on chromosome 5. Positive hits were when confirmed by screening a second time using visual markers on chromosome 2. Both the initial and secondary screens were conducted by dissolving the chemicals in DMSO as described above. [0073] Of the 125 compounds screened, the following 54 compounds were found to have positive results. Of these 54 compounds, 33 has positive, but variable results, and 21 had consistently positive. Compound Name Result 3-aminobutanoic acid Consistently positive 2-isothiocyanatoethylbenzene Consistently positive N-(1-benzylpiperidin-4-yl)-6,7-dimethoxy-2-(4-methyl-1,4-diazepan-1- Consistently positive yl)quinazolin-4-amine 3-Chloro-2-{(Z)-(4-chlorophenyl)[(6-chloro-2- Consistently positive pyridinyl)hydrazono]methyl}-5-(trifluoromethyl)pyridine 4-allyl-5-{[(2-nitrophenyl)thio]methyl}-4H-1,2,4-triazole-3-thiol Consistently positive 4-hydroxybenzohydrazide Consistently positive 5-chloro-N-[(E)-[phenyl(pyridin-2-yl)methylidene]amino]pyridin-2-amine Consistently positive 4-amino-1-[(2R,4S,5R)-4-hydroxy-5-(hydroxymethyl)oxolan-2-yl]-1,3,5- Consistently positive triazin-2-one 3-[4-[(1R,2S)-2-aminocyclopropyl]phenyl]phenol Consistently positive [(1S,2S,4R)-4-[4-[[(1S)-2,3-dihydro-1H-inden-1-yl]amino]pyrrolo[2,3- Consistently positive d]pyrimidin-7-yl]-2-hydroxycyclopentyl]methyl sulfamate (4R)-1-methyl-4-prop-1-en-2-ylcyclohexene Consistently positive S-methyl 1,2,3-benzothiadiazole-7-carbothioate Consistently positive (1R,4R)-1,7,7-trimethylbicyclo[2.2.1]heptan-2-one Consistently positive 4-isothiocyanatobutylbenzene Consistently positive ylamino)propyl]purin-6-amine Consistently positive 1-isothiocyanatobutane Consistently positive 5-methyl-2-propan-2-ylphenol Consistently positive 5'-methoxy-6'-(3-pyrrolidin-1-ylpropoxy)spiro[cyclobutane-1,3'-indole]-2'- Consistently positive amine 6,6-dimethyl-2-methylidenebicyclo[3.1.1]heptane Consistently positive 5,7-dihydroxy-3-(4-hydroxyphenyl)chromen-4-one Consistently positive disodium;6-methyl-2-[4-[2-[4-(6-methyl-7-sulfonato-1,3-benzothiazol-2- Consistently positive yl)phenyl]iminohydrazinyl]phenyl]-1,3-benzothiazole-7-sulfonate methyl 2-benzamido-1-(3-phenylpropyl)benzimidazole-5-carboxylate Variable positive 4-amino-N-(5-methyl-1,2-oxazol-3-yl)benzenesulfonamide Variable positive 3-(furan-2-yl)-3-phenylpropan-1-amine Variable positive 1-isothiocyanato-2-methylpropane Variable positive 2-Amino-3,5-dichlorobenzoic acid Variable positive isothiocyanatoethane Variable positive 3-Methoxybenzo[d]isothiazole 1,1-dioxide Variable positive 8-[[4-methyl-3-[[3-[[3-[[2-methyl-5-[(4,6,8-trisulfonaphthalen-1- Variable positive yl)carbamoyl]phenyl]carbamoyl]phenyl]carbamoylamino]benzoyl]amino]b enzoyl]amino]naphthalene-1,3,5-trisulfonic acid 7-[3-(dimethylamino)propoxy]-6-methoxy-2-(4-methyl-1,4-diazepan-1-yl)- Variable positive N-(1-methylpiperidin-4-yl)quinazolin-4-amine N-(3-chloro-4-methylphenyl)-4-methylthiadiazole-5-carboxamide Variable positive 8-[(6-iodo-1,3-benzodioxol-5-yl)sulfanyl]-9-[3-(propan-2- Variable positive (3R,4S,5R,6R)-4-[(3R,4S,5R,6R)-3,5-dihydroxy-6-(hydroxymethyl)-4- Variable positive [(3R,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyoxan-2- yl]oxy-6-(hydroxymethyl)oxane-2,3,5-triol 4-amino-1-[(2R,3R,4S,5R)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]- Variable positive 1,3,5-triazin-2-one 1-isothiocyanatohexane Variable positive (2E,4E,6R)-7-[4-(dimethylamino)phenyl]-N-hydroxy-4,6-dimethyl-7- Variable positive oxohepta-2,4-dienamide 2,2,2-trifluoroethyl N-[(2S)-3-methyl-1-[(4-methylbenzoyl)amino]butan-2- Variable positive yl]carbamate 4-amino-N-(4,6-dimethylpyrimidin-2-yl)benzenesulfonamide Variable positive 4-amino-N-(6-methoxypyridazin-3-yl)benzenesulfonamide Variable positive 2-cyclohexyl-6-methoxy-N-(1-propan-2-ylpiperidin-4-yl)-7-(3-pyrrolidin- Variable positive 1-ylpropoxy)quinazolin-4-amine 4-amino-N-(5-methoxypyrimidin-2-yl)benzenesulfonamide Variable positive HB2 Variable positive 2-[2-(3,4-dimethoxyphenyl)ethylamino]-6-(3-fluorophenyl)-8H- Variable positive pyrimido[4,5-d]pyrimidine-5,7-dione FN3 Variable positive 4-amino-N-(6-chloropyridazin-3-yl)benzenesulfonamide Variable positive 1-(4-((dimethylamino)methyl)phenyl)-8,9-dihydro-2,7,9a- Variable positive triazabenzo[cd]azulen-6(7H)-one 7-[3-(dimethylamino)propoxy]-6-methoxy-2-(4-methyl-1,4-diazepan-1-yl)- Variable positive N-(1-methylpiperidin-4-yl)quinazolin-4-amine azane;dichloroplatinum(2+) Variable positive 3,5-dichloro-N-(2-methylbut-3-yn-2-yl)benzamide Variable positive 4-[(E)-2-(3,5-dimethoxyphenyl)ethenyl]phenol Variable positive PS27 Variable positive (2E)-3,7-dimethylocta-2,6-dien-1-ol Variable positive 2,2-dimethyl-3-methylidenebicyclo[2.2.1]heptane Variable positive (2S,5R)-5-methyl-2-propan-2-ylcyclohexan-1-one Variable positive [0074] The following chemicals were also tested in sequential treatments to the plant, to see if that further improved meiotic recombination . ^^^^^^^^^ ^^^^^^^^^^^ ^^^^^^^^^ ^^^^^^^^^ ^^^^^^^^^ ^^^^^^ ^^^^^^^^^^ ^^^^^^^^^^ ^^^^^^^^^^ ^^^^^^^^^^ ^^^^^^^ ^^^^^^^^^^^^ ^^^^^^^ 4-amino-1-[(2R,3R,4S,5R)- 4 4 4 0 1.00 3,4-dihydroxy-5- (hydroxymethyl)oxolan-2- yl]-1,3,5-triazin-2-one 5,7-dihydroxy-3-(4- 4 4 4 0 1.00 hydroxyphenyl)chromen-4- one [(1S,2S,4R)-4-[4-[[(1S)-2,3- 4 4 4 0 1.00 dihydro-1H-inden-1- yl]amino]pyrrolo[2,3- d]pyrimidin-7-yl]-2- hydroxycyclopentyl]methyl sulfamate 6,6-dimethyl-2- 4 4 3 0 0.75 methylidenebicyclo[3.1.1]he ptane 4-allyl-5-{[(2- 4 4 3 0 0.75 nitrophenyl)thio]methyl}- 4H-1,2,4-triazole-3-thiol 4-amino-1-[(2R,4S,5R)-4- 4 3 3 0 0.75 hydroxy-5- (hydroxymethyl)oxolan-2- yl]-1,3,5-triazin-2-one 4- 4 4 3 0 0.75 isothiocyanatobutylbenzene 1-isothiocyanato-2- 4 3 3 0 0.75 methylpropane 8-[(6-iodo-1,3-benzodioxol- 4 3 3 0 0.75 5-yl)sulfanyl]-9-[3-(propan- 2- ylamino)propyl]purin-6- 4 4 3 0 0.75 amine (3R,4S,5R,6R)-4- 4 3 3 0 0.75 [(3R,4S,5R,6R)-3,5- dihydroxy-6- (hydroxymethyl)-4- [(3R,4S,5S,6R)-3,4,5- trihydroxy-6- (hydroxymethyl)oxan-2- yl]oxyoxan-2-yl]oxy-6- (hydroxymethyl)oxane- 2,3,5-triol (2E)-3,7-dimethylocta-2,6- 4 3 3 0 0.75 dien-1-ol 2,2-dimethyl-3- 4 3 3 0 0.75 methylidenebicyclo[2.2.1]he ptane 3-Chloro-2-{(Z)-(4- 4 4 2 0 0.50 chlorophenyl)[(6-chloro-2- pyridinyl)hydrazono]methyl }-5- (trifluoromethyl)pyridine 3-[4-[(1R,2S)-2- 4 3 2 0 0.50 aminocyclopropyl]phenyl]ph enol 5-chloro-N-[(E)- 4 3 2 0 0.50 [phenyl(pyridin-2- yl)methylidene]amino]pyridi n-2-amine 7-[3- 4 3 2 0 0.50 (dimethylamino)propoxy]-6- methoxy-2-(4-methyl-1,4- diazepan-1-yl)-N-(1- methylpiperidin-4- yl)quinazolin-4-amine FN3 4 3 2 0 0.50 HB2 4 2 2 0 0.50 2- 4 2 2 0 0.50 isothiocyanatoethylbenzene S-methyl 1,2,3- 4 3 2 0 0.50 benzothiadiazole-7- carbothioate 3-aminobutanoic acid 4 3 2 0 0.50 3- 4 2 2 0 0.50 Methoxybenzo[d]isothiazole 1,1-dioxide 4-amino-N-(6- 4 2 2 0 0.50 chloropyridazin-3- yl)benzenesulfonamide 4-amino-N-(5-methyl-1,2- 4 2 2 0 0.50 oxazol-3- yl)benzenesulfonamide 2-[2-(3,4- 2 1 1 0 0.50 dimethoxyphenyl)ethylamin o]-6-(3-fluorophenyl)-8H- pyrimido[4,5-d]pyrimidine- 5,7-dione (2E,4E,6R)-7-[4- 2 1 1 0 0.50 (dimethylamino)phenyl]-N- hydroxy-4,6-dimethyl-7- oxohepta-2,4-dienamide (2S,5R)-5-methyl-2-propan- 4 2 1 0 0.25 2-ylcyclohexan-1-one N-(1-benzylpiperidin-4-yl)- 4 2 1 0 0.25 6,7-dimethoxy-2-(4-methyl- 1,4-diazepan-1- yl)quinazolin-4-amine isothiocyanatoethane 4 2 1 0 0.25 1-isothiocyanatohexane 4 1 1 0 0.25 4-hydroxybenzohydrazide 4 2 1 0 0.25 [0075] Chemicals were scored on their degree of improvement at one or both chromosomes over each interval. [0076] The screens identified of 3-aminobutanoic acid (BABA) and 2-isothiocyanatoethylbenzene (phenethyl isothiocyanate) as the top two positive results. Application of 3-aminobutanoic acid (BABA), a pathogen shock mimic, resulted in an 87% increase in meiotic recombination, overall, and a 144% increase in meiotic ecombination in interval I5c (See Figure 1). Application of 2- isothiocyanatoethylbenzene (phenethyl isothiocyanate), a heat shock mimic, resulted in an 85% increase in meiotic recombination, overall, and a 170% increase in recombination in interval I2a (all 4 intervals positive). See Figure 2. [0077] Next, two emulsifiable concentrate systems (e.g., Systems 1 and 2) were designed to determine their effect on the uptake of the chemicals, concentration, and impact on meiotic recombination. Chemical name / composition System 1 System 2 Purpose 2-ethylhexan-1-ol (25.0 - 50.0%); Benzenesulfonic acid, 4-C10-13- s_{ec-alkyl derivs., calcium salts (50.0 - 75.0%)} ^{1 1 Emulsifier} polyethoxylated castor oil 5 5 Emulsifier A_{lcohols, C12-18, ethoxylated propoxylated (90.0 - 100.0%) 35 35} ^{Adjuvant (uptake} enhancer) Alcohols, C11-14-iso-, C13-rich, ethoxylated propoxylated (99.4 - Adjuvant (uptake 1_00.0%) ^{8.8 8.8} enhancer) Solvent / carrier / Solven Haphtha (petroleum), heavy aromatic (100%) 5 5 improved emulsion Oxirane, methyl-, polymer with oxirane, mono-C10-16-alkyl ethers, Adjuvant ( for p_{hosphastes (60.0 - 90.0%); phosphoric acid (10.0 - 15.0%)} ^{0 5} acid complexes) Decanamide, N,N-dimethyl (75.0 - 100.0%) 45.3 40.3 Solvent / carrier [0078] The impact on Systems 1 and 2 on meiotic recombination are shown in Figures 3-7. [0079] The foregoing is illustrative of the present invention, and is not to be construed as limiting thereof. The invention is defined by the following claims, with equivalents of the claims to be included therein.

Claims

What is claimed is: 1. A method of modifying meiotic recombination in a plant, the method comprising: applying a compound that modulates meiotic recombination to the plant, thereby modifying meiotic recombination in the plant, wherein the compound is selected from the group consisting of the compound that modulates meiotic recombination is selected from the group consisting of 3-aminobutanoic acid, 2- isothiocyanatoethylbenzene, N-(1-benzylpiperidin-4-yl)-6,7-dimethoxy-2-(4-methyl-1,4-diazepan-1- yl)quinazolin-4-amine, 3-Chloro-2-{(Z)-(4-chlorophenyl)[(6-chloro-2-pyridinyl)hydrazono]methyl}-5- (trifluoromethyl)pyridine, 4-allyl-5-{[(2-nitrophenyl)thio]methyl}-4H-1,2,4-triazole-3-thiol, 4- hydroxybenzohydrazide, 5-chloro-N-[(E)-[phenyl(pyridin-2-yl)methylidene]amino]pyridin-2-amine, 4- amino-1-[(2R,4S,5R)-4-hydroxy-5-(hydroxymethyl)oxolan-2-yl]-1,3,5-triazin-2-one, 3-[4-[(1R,2S)-2- aminocyclopropyl]phenyl]phenol, [(1S,2S,4R)-4-[4-[[(1S)-2,3-dihydro-1H-inden-1-yl]amino]pyrrolo[2,3- d]pyrimidin-7-yl]-2-hydroxycyclopentyl]methyl sulfamate, (4R)-1-methyl-4-prop-1-en-2-ylcyclohexene, S-methyl 1,2,3-benzothiadiazole-7-carbothioate, (1R,4R)-1,7,7-trimethylbicyclo[2.2.1]heptan-2-one, 4- isothiocyanatobutylbenzene, ylamino)propyl]purin-6-amine, 1-isothiocyanatobutane, 5-methyl-2-propan- 2-ylphenol, 5'-methoxy-6'-(3-pyrrolidin-1-ylpropoxy)spiro[cyclobutane-1,3'-indole]-2'-amine, 6,6- dimethyl-2-methylidenebicyclo[3.1.1]heptane, 5,7-dihydroxy-3-(4-hydroxyphenyl)chromen-4-one, disodium;6-methyl-2-[4-[2-[4-(6-methyl-7-sulfonato-1,3-benzothiazol-2- yl)phenyl]iminohydrazinyl]phenyl]-1,3-benzothiazole-7-sulfonate, methyl 2-benzamido-1-(3- phenylpropyl)benzimidazole-5-carboxylate, 4-amino-N-(5-methyl-1,2-oxazol-3-yl)benzenesulfonamide, 3-(furan-2-yl)-3-phenylpropan-1-amine, 1-isothiocyanato-2-methylpropane, 2-Amino-3,5-dichlorobenzoic acid, isothiocyanatoethane, 3-Methoxybenzo[d]isothiazole 1,1-dioxide, 8-[[4-methyl-3-[[3-[[3-[[2-methyl- 5-[(4,6,8-trisulfonaphthalen-1- yl)carbamoyl]phenyl]carbamoyl]phenyl]carbamoylamino]benzoyl]amino]benzoyl]amino]naphthalene- 1,3,5-trisulfonic acid, 7-[3-(dimethylamino)propoxy]-6-methoxy-2-(4-methyl-1,4-diazepan-1-yl)-N-(1- methylpiperidin-4-yl)quinazolin-4-amine, N-(3-chloro-4-methylphenyl)-4-methylthiadiazole-5- carboxamide, 8-[(6-iodo-1,3-benzodioxol-5-yl)sulfanyl]-9-[3-(propan-2-(3R,4S,5R,6R)-4- [(3R,4S,5R,6R)-3,5-dihydroxy-6-(hydroxymethyl)-4-[(3R,4S,5S,6R)-3,4,5-trihydroxy-6- (hydroxymethyl)oxan-2-yl]oxyoxan-2-yl]oxy-6-(hydroxymethyl)oxane-2,3,5-triol, 4-amino-1- [(2R,3R,4S,5R)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]-1,3,5-triazin-2-one, 1- isothiocyanatohexane, (2E,4E,6R)-7-[4-(dimethylamino)phenyl]-N-hydroxy-4,6-dimethyl-7-oxohepta- 2,4-dienamide, 2,2,2-trifluoroethyl N-[(2S)-3-methyl-1-[(4-methylbenzoyl)amino]butan-2-yl]carbamate, 4-amino-N-(4,6-dimethylpyrimidin-2-yl)benzenesulfonamide, 4-amino-N-(6-methoxypyridazin-3- yl)benzenesulfonamide, 2-cyclohexyl-6-methoxy-N-(1-propan-2-ylpiperidin-4-yl)-7-(3-pyrrolidin-1- ylpropoxy)quinazolin-4-amine, 4-amino-N-(5-methoxypyrimidin-2-yl)benzenesulfonamide, HB2, 2-[2- (3,4-dimethoxyphenyl)ethylamino]-6-(3-fluorophenyl)-8H-pyrimido[4,5-d]pyrimidine-5,7-dione, FN3, 4- amino-N-(6-chloropyridazin-3-yl)benzenesulfonamide, 1-(4-((dimethylamino)methyl)phenyl)-8,9- dihydro-2,7,9a-triazabenzo[cd]azulen-6(7H)-one, 7-[3-(dimethylamino)propoxy]-6-methoxy-2-(4-methyl- 1,4-diazepan-1-yl)-N-(1-methylpiperidin-4-yl)quinazolin-4-amine, azane;dichloroplatinum(2+), 3,5- dichloro-N-(2-methylbut-3-yn-2-yl)benzamide, 4-[(E)-2-(3,5-dimethoxyphenyl)ethenyl]phenol, PS27, (2E)-3,7-dimethylocta-2,6-dien-1-ol, 2,2-dimethyl-3-methylidenebicyclo[2.2.1]heptane, and (2S,5R)-5- methyl-2-propan-2-ylcyclohexan-1-one. 2. The method of claim 1, wherein the compound that modulates meiotic recombination is selected from the group consisting of tolprocarb, 4-allyl-5-{[(2-nitrophenyl)thio]methyl}-4H-1,2,4- triazole-3-thiol, 4-[(E)-2-(2-Quinolinyl)vinyl]phenol, 9-(2,3-Dihydroxypropyl)-adenine, 2,2-Dichloro-N- [(1R)-1-(4-chlorophenyl)ethyl]-1-ethyl-3-methylcyclopropanecarboxamide, 2,

2-Dichloro-3,3- dimethylcyclopropanecarboxylic acid, and 3-methyl-2-[(Z)-pent-2-enyl]cyclopent-2-en-1-one. 3. The method of claim 1, wherein the compound that modulates meiotic recombination is selected from the group consisting of propyzamide,

3-Chloro-2-{(2E)-2-[phenyl(2- pyridinyl)methylene]hydrazino}-5-(trifluoromethyl)pyridine, 4-[2-(3,5-Dimethyl-2-oxocyclohexyl)-2- hydroxyethyl]-2,6-piperidi, trifluralin, Caffeine, 1-(Ethylamino)-1-oxo-2-propanyl phenylcarbamate, and 3-Chloro-2-{(Z)-(4-chlorophenyl)[(6-chloro-2-pyridinyl)hydrazono]methyl}-5-(trifluoromethyl)pyridine. 4. The method of claim 1, wherein the compound that modulates meiotic recombination is 4-allyl-5-{[(2-nitrophenyl)thio]methyl}-4H-1,2,

4-triazole-3-thiol or 3-Chloro-2-{(Z)-(4-chlorophenyl)[(6- chloro-2-pyridinyl)hydrazono]methyl}-5-(trifluoromethyl)pyridine.

5. The method of claim 1, wherein the compound that modulates meiotic recombination is 3- aminobutanoic acid (BABA) or 2-isothiocyanatoethylbenzene (phenethyl isothiocyanate).

6. The method of claim 1, wherein the compound that modulates meiotic recombination is selected from the group consisting of 1-isothiocyanatobutane, (1R,4R)-1,7,7- trimethylbicyclo[2.2.1]heptan-2-one, 2-isothiocyanatoethylbenzene, 2-Amino-3,5-dichlorobenzoic acid,5- methyl-2-propan-2-ylphenol, 4-isothiocyanatobutylbenzene and, 4-hydroxybenzohydrazide. 7. The method of claim 1, wherein the compound that modulates meiotic recombination is selected from the group consisting of 5-methyl-2-propan-2-ylphenol, (1R,4R)-1,7,

7- trimethylbicyclo[2.2.1]heptan-2-one, 2-isothiocyanatoethylbenzene, 4-hydroxybenzohydrazide, 2-Amino- 3,5-dichlorobenzoic acid, 4-isothiocyanatobutylbenzene, and 1-isothiocyanatobutane.

8. The method of any one of claims 1-7, wherein the method increases the frequency of meiotic 8.recombination in the plant, optionally wherein the frequency of meiotic recombination in the plant is compared to the frequency of meiotic recombination in a control plant and/or a parent plant and/or wherein the frequency of meiotic recombination is measured using a pollen tetrad-based visual assay, by scoring the segregation of loci whose expression results in observable phenotypes, and/or by genotyping (e.g., genotyping the gametes and/or pollen of the plant).

9. The method of any one of claims 1-7, wherein the method decreases the frequency of meiotic recombination in the plant, optionally wherein the frequency of meiotic recombination in the plant is compared to the frequency of meiotic recombination in a control plant and/or a parent plant and/or wherein the frequency of meiotic recombination is measured using a pollen tetrad-based visual assay, by scoring the segregation of loci whose expression results in observable phenotypes, and/or by genotyping (e.g., genotyping the gametes and/or pollen of the plant).

10. The method of any preceding claim, wherein the method is devoid of genetic engineering to modify meiotic recombination in the plant.

11. The method of any preceding claim, wherein the method increases expression and/or activity of a nucleic acid and/or protein in the plant.

12. The method of any preceding claim, wherein the method decreases expression and/or activity of a nucleic acid and/or protein in the plant

13. The method of any preceding claim, wherein applying the compound that modulates meiotic recombination to the plant comprises exogenously contacting the compound that modulates meiotic recombination to at least a portion of the plant.

14. The method of any preceding claim, wherein applying the compound that modulates meiotic recombination to the plant comprises spraying the compound that modulates meiotic recombination onto at least a portion of the plant.

15. The method of any preceding claim, wherein applying the compound that modulates meiotic recombination to the plant comprises soaking at least a portion of the plant in a composition comprising the compound that modulates meiotic recombination.

16. The method of any preceding claim, wherein applying the compound that modulates meiotic recombination to the plant comprises contacting soil adjacent to the plant with the compound that modulates meiotic recombination, optionally wherein contacting soil adjacent to the plant with the compound that modulates meiotic recombination comprises soil drenching with the compound that modulates meiotic recombination.

17. The method of any preceding claim, wherein the compound that modulates meiotic recombination is a compound that mimics temperature shock in the plant, a compound that mimics pathogen stress in the plant, an allelopathic compound, a compound that inhibits non-homologous end joining (NHEJ) in the plant, a compound that affects helicase activity and/or formation in the plant, a compound that affects epigenetic marks and/or epigenetic modifiers, and/or a compound that affects a component used in a meiotic recombination pathway in the plant.

18. The method of any preceding claim, wherein the compound that modulates meiotic recombination is selected from the group consisting of:

19. The method of any preceding claim, wherein the compound that modulates meiotic recombination is present in a composition and applying the compound that modulates meiotic recombination to the plant comprises applying the composition to the plant.

20. The method of claim 19, wherein the composition is a liquid, optionally wherein the liquid comprises water and/or dimethylsulfoxide.

21. The method of claim 19, wherein the composition comprises at least two emulsifiers, at least two adjuvants and at least two carriers.

22. The method of claim 21, wherein the composition comprises three adjuvants.

23. The method of claim 21 or 22, wherein the compound that modulates meiotic recombination is present in the composition in an amount of about 0.01 mM to about 20 mM.

24. The method of any preceding claim, wherein applying the compound that modulates meiotic recombination to the plant comprises applying the compound that modulates meiotic recombination to the plant at a time prior to, during, and/or after the transition from the vegetative phase to the reproductive phase of the plant, optionally wherein the compound is applied to the plant during the plant’ s reproductive phase.

25. The method of any preceding claim, wherein applying the compound that modulates meiotic recombination to the plant comprises applying the compound that modulates meiotic recombination to a cell of the plant, wherein the cell is a meiocyte and/or is undergoing meiosis, optionally wherein the cell is a vegetative cell.

26. The method of any preceding claim, wherein applying the compound that modulates meiotic recombination to the plant comprises applying the compound that modulates meiotic recombination to the sporophyte generation of the plant to modulate meiotic recombination in the gametophyte generation, optionally wherein the gametophyte generation has an increased number of crossovers compared to the gametophyte generation generated in the absence of a method of the present invention and/or to the parent generation generated in the absence of a method of the present invention.

27. The method of any preceding claim, wherein applying the compound that modulates meiotic recombination to the plant comprises applying the compound that modulates meiotic recombination to a reproductive part of the plant (e.g., flower bud, inflorescence, flower, stamen, pistil, etc.).

28. The method of any preceding claim, wherein applying the compound that modulates meiotic recombination to the plant comprises applying the compound that modulates meiotic recombination to the aerial parts of the plant.

29. The method of any preceding claim, wherein the method improves linkage drag in the plant and/or its progeny.

30. The method of any preceding claim, wherein the method eliminates the need for back crossing or decreases the amount of time for back crossing for the plant and/or its progeny, optionally wherein the method of devoid of a back crossing step.

31. The method of any preceding claim, wherein the plant is a crop plant.

32. The method of any preceding claim, wherein the plant is a monocot.

33. The method of any preceding claim, wherein the plant is a dicot, optionally a eudicot.

34. A method of reducing linkage drag in a plant, increasing recombination in a cold region of a plant genome, and/or reducing the number of backcross generations in a plant breeding method, the method comprising: applying a compound that modulates meiotic recombination to a plant, thereby reducing linkage drag in the plant, increasing recombination in a cold region of the genome of the plant, and/or reducing the number of backcross generations in a plant breeding method including the plant, wherein the compound is selected from the group consisting of the compound that modulates meiotic recombination is selected from the group consisting of 3-aminobutanoic acid, 2-isothiocyanatoethylbenzene, N-(1-benzylpiperidin- 4-yl)-6,7-dimethoxy-2-(4-methyl-1,4-diazepan-1-yl)quinazolin-4-amine, 3-Chloro-2-{(Z)-(4- chlorophenyl)[(6-chloro-2-pyridinyl)hydrazono]methyl}-5-(trifluoromethyl)pyridine, 4-allyl-5-{[(2- nitrophenyl)thio]methyl}-4H-1,2,4-triazole-3-thiol, 4-hydroxybenzohydrazide, 5-chloro-N-[(E)- [phenyl(pyridin-2-yl)methylidene]amino]pyridin-2-amine, 4-amino-1-[(2R,4S,5R)-4-hydroxy-5- (hydroxymethyl)oxolan-2-yl]-1,3,5-triazin-2-one, 3-[4-[(1R,2S)-2-aminocyclopropyl]phenyl]phenol, [(1S,2S,4R)-4-[4-[[(1S)-2,3-dihydro-1H-inden-1-yl]amino]pyrrolo[2,3-d]pyrimidin-7-yl]-2- hydroxycyclopentyl]methyl sulfamate, (4R)-1-methyl-4-prop-1-en-2-ylcyclohexene, S-methyl 1,2,3- benzothiadiazole-7-carbothioate, (1R,4R)-1,7,7-trimethylbicyclo[2.2.1]heptan-2-one, 4- isothiocyanatobutylbenzene, ylamino)propyl]purin-6-amine, 1-isothiocyanatobutane, 5-methyl-2-propan- 2-ylphenol, 5'-methoxy-6'-(3-pyrrolidin-1-ylpropoxy)spiro[cyclobutane-1,3'-indole]-2'-amine, 6,6- dimethyl-2-methylidenebicyclo[3.1.1]heptane, 5,7-dihydroxy-3-(4-hydroxyphenyl)chromen-4-one, disodium;6-methyl-2-[4-[2-[4-(6-methyl-7-sulfonato-1,3-benzothiazol-2- yl)phenyl]iminohydrazinyl]phenyl]-1,3-benzothiazole-7-sulfonate, methyl 2-benzamido-1-(3- phenylpropyl)benzimidazole-5-carboxylate, 4-amino-N-(5-methyl-1,2-oxazol-3-yl)benzenesulfonamide, 3-(furan-2-yl)-3-phenylpropan-1-amine, 1-isothiocyanato-2-methylpropane, 2-Amino-3,5-dichlorobenzoic acid, isothiocyanatoethane, 3-Methoxybenzo[d]isothiazole 1,1-dioxide, 8-[[4-methyl-3-[[3-[[3-[[2-methyl- 5-[(4,6,8-trisulfonaphthalen-1- yl)carbamoyl]phenyl]carbamoyl]phenyl]carbamoylamino]benzoyl]amino]benzoyl]amino]naphthalene- 1,3,5-trisulfonic acid, 7-[3-(dimethylamino)propoxy]-6-methoxy-2-(4-methyl-1,4-diazepan-1-yl)-N-(1- methylpiperidin-4-yl)quinazolin-4-amine, N-(3-chloro-4-methylphenyl)-4-methylthiadiazole-5- carboxamide, 8-[(6-iodo-1,3-benzodioxol-5-yl)sulfanyl]-9-[3-(propan-2-(3R,4S,5R,6R)-4- [(3R,4S,5R,6R)-3,5-dihydroxy-6-(hydroxymethyl)-4-[(3R,4S,5S,6R)-3,4,5-trihydroxy-6- (hydroxymethyl)oxan-2-yl]oxyoxan-2-yl]oxy-6-(hydroxymethyl)oxane-2,3,5-triol, 4-amino-1- [(2R,3R,4S,5R)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]-1,3,5-triazin-2-one, 1- isothiocyanatohexane, (2E,4E,6R)-7-[4-(dimethylamino)phenyl]-N-hydroxy-4,6-dimethyl-7-oxohepta- 2,4-dienamide, 2,2,2-trifluoroethyl N-[(2S)-3-methyl-1-[(4-methylbenzoyl)amino]butan-2-yl]carbamate, 4-amino-N-(4,6-dimethylpyrimidin-2-yl)benzenesulfonamide, 4-amino-N-(6-methoxypyridazin-3- yl)benzenesulfonamide, 2-cyclohexyl-6-methoxy-N-(1-propan-2-ylpiperidin-4-yl)-7-(3-pyrrolidin-1- ylpropoxy)quinazolin-4-amine, 4-amino-N-(5-methoxypyrimidin-2-yl)benzenesulfonamide, HB2, 2-[2- (3,4-dimethoxyphenyl)ethylamino]-6-(3-fluorophenyl)-8H-pyrimido[4,5-d]pyrimidine-5,7-dione, FN3, 4- amino-N-(6-chloropyridazin-3-yl)benzenesulfonamide, 1-(4-((dimethylamino)methyl)phenyl)-8,9- dihydro-2,7,9a-triazabenzo[cd]azulen-6(7H)-one, 7-[3-(dimethylamino)propoxy]-6-methoxy-2-(4-methyl- 1,4-diazepan-1-yl)-N-(1-methylpiperidin-4-yl)quinazolin-4-amine, azane;dichloroplatinum(2+), 3,5- dichloro-N-(2-methylbut-3-yn-2-yl)benzamide, 4-[(E)-2-(3,5-dimethoxyphenyl)ethenyl]phenol, PS27, (2E)-3,7-dimethylocta-2,6-dien-1-ol, 2,2-dimethyl-3-methylidenebicyclo[2.2.1]heptane, and (2S,5R)-5- methyl-2-propan-2-ylcyclohexan-1-one.

35. The method of claim 34, wherein the compound that modulates meiotic recombination is selected from the group consisting of tolprocarb, 4-allyl-5-{[(2-nitrophenyl)thio]methyl}-4H-1,2,4- triazole-3-thiol, 4-[(E)-2-(2-Quinolinyl)vinyl]phenol, 9-(2,3-Dihydroxypropyl)-adenine, 2,2-Dichloro-N- [(1R)-1-(4-chlorophenyl)ethyl]-1-ethyl-3-methylcyclopropanecarboxamide, 2,2-Dichloro-3,3- dimethylcyclopropanecarboxylic acid, and 3-methyl-2-[(Z)-pent-2-enyl]cyclopent-2-en-1-one.

36. The method of claim 34, wherein the compound that modulates meiotic recombination is selected from the group consisting of propyzamide, 3-Chloro-2-{(2E)-2-[phenyl(2- pyridinyl)methylene]hydrazino}-5-(trifluoromethyl)pyridine, 4-[2-(3,5-Dimethyl-2-oxocyclohexyl)-2- hydroxyethyl]-2,6-piperidi, trifluralin, Caffeine, 1-(Ethylamino)-1-oxo-2-propanyl phenylcarbamate, and 3-Chloro-2-{(Z)-(4-chlorophenyl)[(6-chloro-2-pyridinyl)hydrazono]methyl}-5-(trifluoromethyl)pyridine.

37. The method of claim 34, wherein the compound that modulates meiotic recombination is 4-allyl-5-{[(2-nitrophenyl)thio]methyl}-4H-1,2,4-triazole-3-thiol or 3-Chloro-2-{(Z)-(4-chlorophenyl)[(6- chloro-2-pyridinyl)hydrazono]methyl}-5-(trifluoromethyl)pyridine.

38. The method of claim 34, wherein the compound that modulates meiotic recombination is 3-aminobutanoic acid (BABA) or 2-isothiocyanatoethylbenzene (phenethyl isothiocyanate).

39. The method of claim 34, wherein the compound that modulates meiotic recombination is selected from the group consisting of 1-isothiocyanatobutane, (1R,4R)-1,7,7- trimethylbicyclo[2.2.1]heptan-2-one, 2-isothiocyanatoethylbenzene, 2-Amino-3,5-dichlorobenzoic acid,5- methyl-2-propan-2-ylphenol, 4-isothiocyanatobutylbenzene and, 4-hydroxybenzohydrazide.

40. The method of claim 34, wherein the compound that modulates meiotic recombination is selected from the group consisting of 5-methyl-2-propan-2-ylphenol, (1R,4R)-1,7,7- trimethylbicyclo[2.2.1]heptan-2-one, 2-isothiocyanatoethylbenzene, 4-hydroxybenzohydrazide, 2-Amino- 3,5-dichlorobenzoic acid, 4-isothiocyanatobutylbenzene, and 1-isothiocyanatobutane.

41. The method of any one of claims 34-40, wherein the method increases the frequency of meiotic recombination in the plant, optionally wherein the frequency of meiotic recombination in the plant is compared to the frequency of meiotic recombination in a control plant and/or a parent plant and/or wherein the frequency of meiotic recombination is measured using a pollen tetrad-based visual assay, by scoring the segregation of loci whose expression results in observable phenotypes, and/or by genotyping (e.g., genotyping the gametes and/or pollen of the plant).

42. The method of any one of claims 34-40, wherein the method decreases the frequency of meiotic recombination in the plant, optionally wherein the frequency of meiotic recombination in the plant is compared to the frequency of meiotic recombination in a control plant and/or a parent plant and/or wherein the frequency of meiotic recombination is measured using a pollen tetrad-based visual assay, by scoring the segregation of loci whose expression results in observable phenotypes, and/or by genotyping (e.g., genotyping the gametes and/or pollen of the plant).

43. The method of any one of claims 34-42, wherein the method is devoid of genetic engineering to modify meiotic recombination in the plant.

44. The method of any one of claims 34-43, wherein the method increases expression and/or activity of a nucleic acid and/or protein in the plant.

45. The method of any one of claims 34-43, wherein the method decreases expression and/or activity of a nucleic acid and/or protein in the plant.

46. The method of any one of claims 34-45, wherein applying the compound that modulates meiotic recombination to the plant comprises exogenously contacting the compound that modulates meiotic recombination to at least a portion of the plant.

47. The method of any one of claims 34-45 wherein applying the compound that modulates meiotic recombination to the plant comprises spraying the compound that modulates meiotic recombination onto at least a portion of the plant.

48. The method of any one of claims 34-45, wherein applying the compound that modulates meiotic recombination to the plant comprises soaking at least a portion of the plant in a composition comprising the compound that modulates meiotic recombination.

49. The method of any one of claims 34-45, wherein applying the compound that modulates meiotic recombination to the plant comprises contacting soil adjacent to the plant with the compound that modulates meiotic recombination, optionally wherein contacting soil adjacent to the plant with the compound that modulates meiotic recombination comprises soil drenching with the compound that modulates meiotic recombination.

50. The method of any one of claims 34-45, wherein the compound that modulates meiotic recombination is present in a composition and applying the compound that modulates meiotic recombination to the plant comprises applying the composition to the plant.

51. The method of claim 50, wherein the composition is a liquid, optionally wherein the liquid comprises water and/or dimethylsulfoxide.

52. The method of claim 50, wherein the composition comprises at least two emulsifiers, at least two adjuvants and at least two carriers.

53. The method of claim 52, wherein the composition comprises three adjuvants.

54. The method of claim 34-53, wherein the compound that modulates meiotic recombination is present in the composition in an amount of about 0.01 mM to about 20 mM.

55. The method of any one of claims 34-54, wherein applying the compound that modulates meiotic recombination to the plant comprises applying the compound that modulates meiotic recombination to the plant at a time prior to, during, and/or after the transition from the vegetative phase to the reproductive phase of the plant, optionally wherein the compound is applied to the plant during the plant’ s reproductive phase.

56. The method of any one of claims 34-54, wherein applying the compound that modulates meiotic recombination to the plant comprises applying the compound that modulates meiotic recombination to a cell of the plant, wherein the cell is a meiocyte and/or is undergoing meiosis, optionally wherein the cell is a vegetative cell.

57. The method of any one of claims 34-54, wherein applying the compound that modulates meiotic recombination to the plant comprises applying the compound that modulates meiotic recombination to the sporophyte generation of the plant to modulate meiotic recombination in the gametophyte generation, optionally wherein the gametophyte generation has an increased number of crossovers compared to the gametophyte generation generated in the absence of a method of the present invention and/or to the parent generation generated in the absence of a method of the present invention.

58. The method of any one of claims 34-54, wherein applying the compound that modulates meiotic recombination to the plant comprises applying the compound that modulates meiotic recombination to a reproductive part of the plant (e.g., flower bud, inflorescence, flower, stamen, pistil, etc.).

59. The method of any one of claims 34-54, wherein applying the compound that modulates meiotic recombination to the plant comprises applying the compound that modulates meiotic recombination to the aerial parts of the plant.

60. The method of any one of claims 34-59, wherein the method reduces linkage drag in the plant and/or its progeny.

61. The method of one of claims 34-60, wherein the method reduces the number of backcross generations in a plant breeding method including the plant, optionally wherein the method eliminates the need for back crossing or decreases the amount of time for back crossing for the plant and/or its progeny, further optionally wherein the method of devoid of a back crossing step.

62. The method of any one of claims 34-61, wherein the method increases recombination in a cold region of the genome of the plant.

63. The method of any one of claims 34-62, wherein the plant is a crop plant.

64. The method of any one of claims 34-63, wherein the plant is a monocot.

65. The method of any one of claims 34-63, wherein the plant is a dicot, optionally a eudicot.